# **INVITATION TO BID**



health

Department: Health REPUBLIC OF SOUTH AFRICA

# HP02-2021AI

# SUPPLY AND DELIVERY OF ANTI-INFECTIVE MEDICINES (ANTIBIOTICS, ANTIFUNGAL, ANTIPROTOZOAL AND ANTIVIRAL AGENTS) TO THE DEPARTMENT OF HEALTH FOR THE PERIOD 1 OCTOBER 2021 TO 30 SEPTEMBER 2023

# **BID VALIDITY PERIOD: 120 DAYS**

No Briefing Session will be held

All tender related enquiries can be mailed to tenders@health.gov.za

## CONTACT PERSONS AT THE NATIONAL DEPARTMENT OF HEALTH

Please direct any queries relating to the bidding process to tenders@health.gov.za

### BID DOCUMENTS FOR COMPLETION AND SUBMISSION

All bid documents listed below must be sorted, filed and submitted in the exact compilation sequence as indicated below and in Annexure A attached.

Submission of bid documents is mandatory, unless it's not applicable and indicated as such in the "N/A" column in the Bid Document Check List.

## All bid documents must be signed.

Bidders not complying to any of the requirements will be deemed to be non-responsive and will not be considered for evaluation.

- Covering Letter i.e. limited stock availability of any item offered, non-compliance;
- Status relating to TAX, B-BBEE, License to Manufacture, Certificates etc. Bid Signature;
- Resolution/Authority to sign bid;
- Bid/File Index;
- PBD 4.1: Contact Details of Bidder;
- SBD 1: Invitation to bid;
- Tax Clearance Pin Issued;
- CSD Registration report A certified copy of latest and complete report. Note: CSD summary report will not be accepted;
- SBD 4: Declaration of interest;
- PBD9: Directors: Categorisation by race, gender and disability;
- SBD5: The National Industrial Participation Programme;
- SBD 6(1): Preference Points Claimed (B-BBEE);
- Valid B-BBEE certificate (certified copy) or Sworn Affidavit to claim preference points;
- SBD 8: Declaration of Past SCM Practices;
- SBD 9: Certificate of Independent Bid Determination;
- PBD1: Authorisation Declaration Note: Non-compliance to submission of a valid authorisation declaration, where applicable, may invalidate the bid;
- PBD 1.1: List of products offered sourced from third party;
- PBD 1.2: Unconditional written undertaking from the third party;
- PBD5: Good Manufacturing Practice (GMP). Declaration of compliance;
- PBD 8: Special Requirements and Conditions of Contact. Declaration of compliance;

- CIPC/CIPRO or proof of ownership/shareholding. Certified copies of registration certificates;
- Proof of company cedings, mergers and name changes;
- Certified copy of Licence to manufacture or import (in the name of the bidder), including all annexures;
- Certified copy of Licence to manufacture medicines, including all annexures for <u>local</u> <u>manufacturing</u> sites as listed on the MRC of the bidder (applicant);
- Certified copies of Medicine Registration Certificates (MRC) <u>with all the associated</u> <u>conditions of registration (Annexure).</u> Note: All MRC's must be marked by the bidder with the relevant item number and be sorted and filed in numerical order;
- Original Package Insert (PI) or document detailing professional information approved by the Medicines Control Council (MCC) or the South African Health Products Regulatory Authority (SAHPRA) for each product offered. Note: All PI's must be marked with the relevant item number and be sorted and filed/submitted in numerical
- order;
- Proof of sample submission;
- Bidder's item list (List of products offered); and
- Signed Excel Bid Response Pricing Schedule (All prices must be submitted in 2 (two) decimals). If the Excel Bid Response Pricing Schedule is not signed in the space provided, the bid will not be considered for evaluation.

# COMPLETION OF DOCUMENTS AND BID SUBMISSION

Bidders are required to submit three sets of bid documents according to the instructions below. All three sets must be submitted not later than the closing date and time. Set 2 and Set 3 must be included on a CD with Set 1 submitted in a sealed package. The full name and address of the bidder, including the return address, the bid number and the closing date must be clearly indicated on the package. All fields must be completed. Where information requested is not relevant this should be indicated with N/A.

## Set 1: Hard copy (legally binding bid documents)

Bidders must complete all SBD, PBD and Bid Response forms in black ink, typed. Where no electronic entry field is provided bidders must complete the forms in black ink, handwritten in capital letters. The signed hard copy of the bid document will serve as the legal bid document.

Executive Officer, Chief Financial Officer, or authorised designee of the entity submitting the bid must sign the official signature pages. All pages in the complete bid document must be initialed by same with black ink. The use of correction fluid is not acceptable. Any change/s must be clearly indicated and initialed.

As the National Department of Health complies with the regulations made under the Disaster Management Act, 2002, published in the Gazette 18 March 2020 no briefing session or public bid opening will be held. However, Bidders must still ensure that bids are delivered on time to the correct address and deposited in the Tender Box. Late bids will not be accepted for consideration.

Bidders must refrain from using binding methods like coil, comb, wire velobind, screw binding etc. It is requested that bidders pre-punch two holes on the left hand side of bid documents suitable for filing in a two hole lever arch file. Bid documents should be tied in parcels using string or rope that can be easily untied for filing purposes.

## Set 2: PDF of Hard Copy, signed legal documents. (i.e. pdf of Set 1)

Bidders must submit a PDF version of the entire signed hardcopy bid, including all certificates and documents requested.

## Set 3: Electronic version of bid documents

Bidders must submit the electronic versions (editable pdf) of all SBD and PBD documents, Bid Response Document and other relevant spreadsheets in Excel (not pdf).

All three sets of information must be submitted in order for the bid to be evaluated.

Bidders must ensure that the price quoted for a product (line item) on the Excel Bid Response Document is for the unit pack specified. No conversion factors will be applied.

## **INVITATION TO BID**

# YOU ARE HEREBY INVITED TO BID FOR REQUIREMENTS OF THE NATIONAL DEPARTMENT OF HEALTH

## BID NUMBER: HP02-2021AI CLOSING DATE: 30 NOVEMBER 2020 CLO

CLOSING TIME:11:00

### DESCRIPTION Supply and Delivery of Anti-Infective Medicines (Antibiotics, Antifungal, Antiprotozoal and Antiviral Agents) to the Department of Health for the period 1 October 2021 to 30 September 2023

Bid documents must be addressed as follows and delivered before the closing date and time:

#### Addressed to:

The Director-General: Health Civitas Building C/o Struben and Thabo Sehume Streets, Pretoria

#### **Delivered to:**

Pharmaceutical Tender Box Reception Area National Department of Health Civitas Building, C/o Struben and Thabo Sehume Streets, Pretoria

Bidders should ensure that bids are delivered on time to the correct address and deposited in the Pharmaceutical Tender Box. Late bids will not be accepted for consideration

The Pharmaceutical Tender Box is generally accessible during extended working hours.

See below for map locating Civitas Building within Pretoria Central Business District.



ALL BIDS MUST BE SUBMITTED ON THE OFFICIAL FORMS

This competitive bidding process is subject to the Preferential Procurement Policy Framework Act and the Preferential Procurement Regulations, 2011, the General Conditions of Contract (GCC) and, if applicable, any other Special Requirements and Conditions of Contract.



Private Bag X828, PRETORIA, 0001. Civitas Building Cnr Thabo Sehume & Struben Streets, PRETORIA 0001 Directorate: Affordable Medicines

Ref: HP02-2021AI

e-mail: tenders@health.gov.za

#### INVITATION TO BID: HP02-2021AI: SUPPLY AND DELIVERY OF ANTI-INFECTIVE MEDICINES (ANTIBIOTICS, ANTIFUNGAL, ANTIPROTOZOAL AND ANTIVIRAL AGENTS) TO THE DEPARTMENT OF HEALTH FOR THE PERIOD 1 OCTOBER 2021 TO 30 SEPTEMBER 2023

- 1. Kindly furnish the Department of Health with a tender for the supplies shown on the attached forms.
- 2. Included are the General Conditions of Contract (GCC), Special Requirements and Conditions of Contract (SRCC) as well as the Standard Bidding Document (SBD) and Pharmaceutical Bidding Document (PBD) forms listed on the annexure hereto. The Bid Response Document is available as a separate Excel file.
- 3. The complete document with the attached forms must be completed in detail and returned with your bid. (Invitation to Bid document, all pages). Each bid document must be submitted along with a CD with the electronic bid format as specified in a sealed package with the following information on the outside of the package: Bid Number and Closing date of Bid, full name and address of the Bidder, including the return address and full name of contact person.
- 4. The bid must be addressed to the Director-General, Department of Health, and be deposited into the pharmaceutical tender box as indicated on the SBD1 form not later than the closing date and time of the bid. The tender box is located at the main entrance of the Department of Health, Civitas building, located on the corner of Struben and Thabo Sehume Streets, Pretoria.

& Janasoo Fren

Ms K Jamaloodien DIRECTOR: AFFORDABLE MEDICINES For: Director-General Date:

		REQUIREMENTS OF TH	HE NATION					44.00
	-2021AI CLOSING DATE: 30 NOVEMBER 2020 CLOSING TIME: 11:00							
ANTIVIRAL AGENTS) TO THE DEPARTMENT OF HEALTH FOR THE PERIOD 1 OCTOBER 2021 TO 30 SEPTEMBER 2023								
BID RESPONSE DOCUMENTS MAY BE DEPOSITED IN THE BID BOX SITUATED AT C/O STRUBEN AND THABO SEHUME STREETS								
PHARMACEUTICAL TE	NDER BOX							
RECEPTION AREA								
NATIONAL DEPARTMENT OF HEALTH								
CIVITAS BUILDING								
BIDDING PROCEDURE	ENQUIRIES MAY	BE DIRECTED TO	TECHNIC	CAL E	NQUIRIES MAY	BE DIR	ECTED TO:	
CONTACT PERSON			CONTAC	T PER	RSON			
TELEPHONE NUMBER		TELEPHO	TELEPHONE NUMBER					
FACSIMILE NUMBER			FACSIMI	LE NU	JMBER			_
E-MAIL ADDRESS	TENDERS@HE	ALTH.GOV.ZA	E-MAIL A	DDR	ESS		TENDERS@	HEALTH.GOV.ZA
NAME OF BIDDER								
POSTAL ADDRESS								
STREET ADDRESS								
TELEPHONE NUMBER	CODE			NILIN	1BER			
CELLPHONE NUMBER				NUIV				
FACSIMILE NUMBER	CODE			NILIM	1BER			
E-MAIL ADDRESS				NON				
VAT REGISTRATION								
NUMBER SUPPLIER	TAX				CENTRAL			
COMPLIANCE	COMPLIANCE				SUPPLIER			
STATUS	SYSTEM PIN:		OR		DATABASE No:	MAAA		
B-BBEE STATUS	TICK AP	L PLICABLE BOX]	B-BBEE \$	STAT	US LEVEL SWO			ICABLE BOX]
LEVEL VERIFICATION		-	AFFIDAV	ΊT			-	-
CERTIFICATE	🗌 Yes	🗌 No					🗌 Yes	🗌 No
						450 0		
		ATION CERTIFICATE/ NCE POINTS FOR B-B		AFFI	DAVII (FOR EI	WES &	QSES) MUST BE	SUBMITTED IN
ARE YOU THE ACCREDITED								
REPRESENTATIVE IN					DREIGN BASED R THE GOODS		∐Yes	□No
SOUTH AFRICA FOR THE GOODS	Yes	No			ORKS OFFERE	D?	[IF YES, ANSWE	
/SERVICES /WORKS	[IF YES ENCLO	SE PROOF]					QUESTIONNAIRE	
OFFERED?								
QUESTIONNAIRE TO B	IDDING FOREIGN	SUPPLIERS						
IS THE ENTITY A RESID	DENT OF THE REP	PUBLIC OF SOUTH AFRI	CA (RSA)?	1			I YI	ES 🗌 NO
DOES THE ENTITY HAV	/E A BRANCH IN T	THE RSA?					🗌 YE	ES 🗌 NO
DOES THE ENTITY HAV	/E A PERMANENT	ESTABLISHMENT IN TH	HE RSA?				🗌 YI	ES 🗌 NO
DOES THE ENTITY HAV	/E ANY SOURCE	OF INCOME IN THE RSA	\?				🗌 YE	ES 🗌 NO
IF THE ANSWER IS "N	IS THE ENTITY LIABLE IN THE RSA FOR ANY FORM OF TAXATION?							

**BID SUBMISSION:** 

1.

1.1. BIDS MUST BE DELIVERED BY THE STIPULATED TIME TO TH E CORRECT ADDRESS. LATE BIDS WILL NOT BE ACCEPTED FOR

	CONSIDERATION.
1.2.	ALL BIDS MUST BE SUBMITTED ON THE OFFICIAL FORMS PROVIDED-(NOT TO BE RE-TYPED) OR IN THE MANNER PRESCRIBED IN THE BID DOCUMENT.
1.3.	THIS BID IS SUBJECT TO THE PREFERENTIAL PROCUREME NT POLICY FRAMEWORK ACT, 2000 AND THE PREFERENTIAL PROCUREMENT REGULATIONS, 2017, THE GENERAL CONDITIONS OF CONTRACT (GCC) AND, IF APPLICABLE, ANY OTHER SPECIAL CONDITIONS OF CONTRACT.
	THE SUCCESSFUL BIDDER WILL BE REQUIRED TO FILL IN AND SIGN A WRITTEN CONTRACT FORM (SBD7).
2.	TAX COMPLIANCE REQUIREMENTS
2.1	BIDDERS MUST ENSURE COMPLIANCE WITH THEIR TAX OBLIGATIONS.
2.2	BIDDERS ARE REQUIRED TO SUBMIT THEIR UNIQUE PERSONAL IDENTIFICATION NUMBER (PIN) ISSUED BY SARS TO ENABLE THE ORGAN OF STATE TO VERIFY THE TAXPAYER'S PROFILE AND TAX STATUS.
2.3	APPLICATION FOR TAX COMPLIANCE STATUS (TCS) PIN MAY BE MADE VIA E-FILING THROUGH THE SARS WEBSITE WWW.SARS.GOV.ZA.
2.4	BIDDERS MAY ALSO SUBMIT A PRINTED TCS CERTIFICATE TOGETHER WITH THE BID.
2.5	IN BIDS WHERE CONSORTIA / JOINT VENTURES / SUB-CONTRACTORS ARE INVOLVED, EACH PARTY MUST SUBMIT A SEPARATE TCS CERTIFICATE / PIN / CSD NUMBER.
2.6	WHERE NO TCS PIN IS AVAILABLE BUT THE BIDDER IS REGI STERED ON THE CENTRAL SUPPLIER DATABASE (CSD), A CSD NUMBER MUST BE PROVIDED.
2.7	NO BIDS WILL BE CONSIDERED FROM PERSONS IN THE SERVI CE OF THE STATE, COMPANIES WITH DIRECTORS WHO ARE PERSONS IN THE SERVICE OF THE STATE, OR CLOSE CORPORATIONS WITH MEMBERS PERSONS IN THE SERVICE OF THE STATE."
NB:	FAILURE TO PROVIDE / OR COMPLY WITH ANY OF THE ABOVE PARTICULARS MAY RENDER THE BID INVALID.
SIG	NATURE OF BIDDER:

.....

CAPACITY UNDER WHICH THIS BID IS SIGNED: (Proof of authority must be submitted e.g. company resolution)

DATE:



Private Bag X828, PRETORIA, 0001. Civitas Building Cnr Thabo Sehume & Struben Streets, PRETORIA 0001 Directorate: Access to Affordable Medicines Tel: (012) 395 8130 Fax: (012) 395 8823/4

#### CONTRACT NUMBER:

#### SUPPLIER DETAILS:

Note that Provincial Departments of Health will require separate registration of suppliers on their Databases & could request completion of Province-specific documents.

If a contract is awarded, full detail for supplier registration or verification will be requested.

Should any of the detail provided below change, please advise the National Department of Health immediately in writing with detail of such change(s).

#### CONTACT DETAIL

1. Supplier F Legal entity / with bank	correspor					
2. Contact person regarding contract enquiries (to be printed on contract cover)						
Name & Surname				e-mail		-
Telephone				Fax		
Cell				Other		
3. Contact regarding orders						
Address for posting of orders			Fax			
				Tel (confirmation)		
				EDI		
Order	Name &	surname:		Tel		
enquiries				e-mail		
4. National key Account Manager (or Tender Manager)						
Name				e-mail		
Telephone				Cell		

PBD4.1

#### SIGNATURE FOR PBD4.1

I / we, the undersigned, herewith certify that all of the above information is correct at the time of completion. I/ we furthermore certify that I / we have the appropriate authority to furnish the above-mentioned information on behalf of our employer.

Name:	Signature
	-
Designation:	Date

Name:	Signature
Designation	Data
Designation:	Date

#### PREFERENCE POINTS CLAIM FORM IN TERMS OF THE PREFERENTIAL PROCUREMENT REGULATIONS 2017

This preference form must form part of all bids invited. It contains general information and serves as a claim form for preference points for Broad-Based Black Economic Empowerment (B-BBEE) Status Level of Contribution

#### NB: BEFORE COMPLETING THIS FORM, BIDDERS MUST STUDY THE GENERAL CONDITIONS, DEFINITIONS AND DIRECTIVES APPLICABLE IN RESPECT OF B-BBEE, AS PRESCRIBED IN THE PREFERENTIAL PROCUREMENT REGULATIONS, 2017.

#### 1. GENERAL CONDITIONS

- 1.1 The following preference point systems are applicable to all bids:
  - the 80/20 system for requirements with a Rand value of up to R50 000 000 (all applicable taxes included); and
  - the 90/10 system for requirements with a Rand value above R50 000 000 (all applicable taxes included).

#### 1.2

- a) The value of this bid is estimated to exceed R50 000 000 (all applicable taxes included) and therefore the 90/10 preference point system shall be applicable; or
- b) Either the 80/20 or 90/10 preference point system will be applicable to this tender (*delete whichever is not applicable for this tender*).
- 1.3 Points for this bid shall be awarded for:
  - (a) Price; and
  - (b) B-BBEE Status Level of Contributor.
- 1.4 The maximum points for this bid are allocated as follows:

	POINTS
PRICE	90
B-BBEE STATUS LEVEL OF CONTRIBUTOR	10
Total points for Price and B-BBEE must not exceed	100

- 1.5 Failure on the part of a bidder to submit proof of B-BBEE Status level of contributor together with the bid, will be interpreted to mean that preference points for B-BBEE status level of contribution are not claimed.
- 1.6 The purchaser reserves the right to require of a bidder, either before a bid is adjudicated or at any time subsequently, to substantiate any claim in regard to preferences, in any manner required by the purchaser.

(a) **"B-BBEE"** means broad-based black economic empowerment as defined in section 1 of the Broad-Based Black Economic Empowerment Act;

2

- (b) "**B-BBEE status level of contributor**" means the B-BBEE status of an entity in terms of a code of good practice on black economic empowerment, issued in terms of section 9(1) of the Broad-Based Black Economic Empowerment Act;
- (c) "**bid**" means a written offer in a prescribed or stipulated form in response to an invitation by an organ of state for the provision of goods or services, through price quotations, advertised competitive bidding processes or proposals;
- (d) **"Broad-Based Black Economic Empowerment Act"** means the Broad-Based Black Economic Empowerment Act, 2003 (Act No. 53 of 2003);
- (e) "EME" means an Exempted Micro Enterprise in terms of a code of good practice on black economic empowerment issued in terms of section 9 (1) of the Broad-Based Black Economic Empowerment Act;
- (f) **"functionality"** means the ability of a tenderer to provide goods or services in accordance with specifications as set out in the tender documents.
- (g) "prices" includes all applicable taxes less all unconditional discounts;
- (h) "proof of B-BBEE status level of contributor" means:
  - 1) B-BBEE Status level certificate issued by an authorized body or person;
  - 2) A sworn affidavit as prescribed by the B-BBEE Codes of Good Practice;
  - 3) Any other requirement prescribed in terms of the B-BBEE Act;
- (i) "QSE" means a qualifying small business enterprise in terms of a code of good practice on black economic empowerment issued in terms of section 9 (1) of the Broad-Based Black Economic Empowerment Act;
- *(j)* **"rand value"** means the total estimated value of a contract in Rand, calculated at the time of bid invitation, and includes all applicable taxes;

## 3. POINTS AWARDED FOR PRICE

### 3.1 THE 80/20 OR 90/10 PREFERENCE POINT SYSTEMS

A maximum of 80 or 90 points is allocated for price on the following basis: 80/20 or 90/10

 $Ps = 80\left(1 - \frac{Pt - P\min}{P\min}\right)$  or  $Ps = 90\left(1 - \frac{Pt - P\min}{P\min}\right)$ Where

Ps = Points scored for price of bid under consideration

Pt = Price of bid under consideration

Pmin = Price of lowest acceptable bid

## 4. POINTS AWARDED FOR B-BBEE STATUS LEVEL OF CONTRIBUTOR

4.1 In terms of Regulation 6 (2) and 7 (2) of the Preferential Procurement Regulations, preference points must be awarded to a bidder for attaining the B-BBEE status level of contribution in accordance with the table below:

B-BBEE Status Level of Contributor	Number of points (90/10 system)	Number of points (80/20 system)
1	10	20
2	9	18
3	6	14
4	5	12
5	4	8
6	3	6
7	2	4
8	1	2
Non-compliant contributor	0	0

#### 5. BID DECLARATION

5.1 Bidders who claim points in respect of B-BBEE Status Level of Contribution must complete the following:

# 6. B-BBEE STATUS LEVEL OF CONTRIBUTOR CLAIMED IN TERMS OF PARAGRAPHS 1.4 AND 4.1

6.1 B-BBEE Status Level of Contributor: . = ......(maximum of 10 or 20 points)

(Points claimed in respect of paragraph 7.1 must be in accordance with the table reflected in paragraph 4.1 and must be substantiated by relevant proof of B-BBEE status level of contributor.

#### 7. SUB-CONTRACTING

7.1 Will any portion of the contract be sub-contracted?

#### (*Tick applicable box*)

YES	NO	

7.1.1 If yes, indicate:

i)	What	percentage	of	the	contract	will	be
	subcontra	cted		%			

- ii) The name of the sub-contractor.....iii) The B-BBEE status level of the sub-contractor.....
- iv) Whether the sub-contractor is an EME or QSE (*Tick applicable box*)
  - YES NO
- v) Specify, by ticking the appropriate box, if subcontracting with an enterprise in terms of Preferential Procurement Regulations,2017:

Designated Group: An EME or QSE which is at last 51% owned	EME	QSE
by:		
Black people		
Black people who are youth		
Black people who are women		
Black people with disabilities		
Black people living in rural or underdeveloped areas or townships		
Cooperative owned by black people		

Page 3 of 5

Any EME	
Any EME	
Any QSE	

#### 8. **DECLARATION WITH REGARD TO COMPANY/FIRM** 8.1 Name of company/firm:..... 8.2 VAT registration number:.... 8.3 Company registration number:.... 8.4 TYPE OF COMPANY/ FIRM Partnership/Joint Venture / Consortium One person business/sole propriety **Close** corporation $\square$ Company (Pty) Limited [TICK APPLICABLE BOX] 8.5 DESCRIBE PRINCIPAL BUSINESS ACTIVITIES ..... ..... ..... ..... 8.6 COMPANY CLASSIFICATION Manufacturer Supplier Professional service provider Other service providers, e.g. transporter, etc. [TICK APPLICABLE BOX]

- 8.7 Total number of years the company/firm has been in business:.....
- 8.8 I/we, the undersigned, who is / are duly authorised to do so on behalf of the company/firm, certify that the points claimed, based on the B-BBE status level of contributor indicated in paragraphs 1.4 and 6.1 of the foregoing certificate, qualifies the company/ firm for the preference(s) shown and I / we acknowledge that:
  - i) The information furnished is true and correct;
  - ii) The preference points claimed are in accordance with the General Conditions as indicated in paragraph 1 of this form;
  - iii) In the event of a contract being awarded as a result of points claimed as shown in paragraphs 1.4 and 6.1, the contractor may be required to furnish documentary proof to the satisfaction of the purchaser that the claims are correct;
  - iv) If the B-BBEE status level of contributor has been claimed or obtained on a

5

fraudulent basis or any of the conditions of contract have not been fulfilled, the purchaser may, in addition to any other remedy it may have –

- (a) disqualify the person from the bidding process;
- (b) recover costs, losses or damages it has incurred or suffered as a result of that person's conduct;
- (c) cancel the contract and claim any damages which it has suffered as a result of having to make less favourable arrangements due to such cancellation;
- (d) recommend that the bidder or contractor, its shareholders and directors, or only the shareholders and directors who acted on a fraudulent basis, be restricted by the National Treasury from obtaining business from any organ of state for a period not exceeding 10 years, after the *audi alteram partem* (hear the other side) rule has been applied; and
- (e) forward the matter for criminal prosecution.

WITNESSES	
1	SIGNATURE(S) OF BIDDERS(S)
2	DATE:
	ADDRESS

#### DIRECTORS: CATEGORISATION OF RACE, GENDER AND DISABILITY <u>COMPLETE ALL FIELDS ELECTRONICALLY AND SIGN</u>

Full Names	Surname	Identity Number or foreigner Passport Number	Age (Number)	Race	Gender (Male/Female)	Disability (Yes/No)
	Complete electro				6	_
				¥	achee	
				I file at		
			Le Et	c <sup>e.</sup>		
			INETIN			
		ally'				
	etro	onic				
	teeleu					
	comple					

#### DECLARATION OF INTEREST

- 1. Any legal person, including persons employed by the state<sup>1</sup>, or persons having a kinship with persons employed by the state, including a blood relationship, may make an offer or offers in terms of this invitation to bid (includes an advertised competitive bid, a limited bid, a proposal or written price quotation). In view of possible allegations of favouritism, should the resulting bid, or part thereof, be awarded to persons employed by the state, or to persons connected with or related to them, it is required that the bidder or his/her authorized representative declare his/her position in relation to the evaluating/adjudicating authority where-
  - the bidder is employed by the state; and/or
  - the legal person on whose behalf the bidding document is signed, has a relationship with persons/a person who are/is involved in the evaluation and or adjudication of the bid(s), or where it is known that such a relationship exists between the person or persons for or on whose behalf the declarant acts and persons who are involved with the evaluation and or adjudication of the bid.

#### 2. In order to give effect to the above, the following questionnaire must be completed and submitted with the bid. 2.1 Full name of bidder : 2.1.1 Represented by (Full Name): 2.2 **Identity Number:** 2.3 Position occupied in the company (director, trustee, shareholder, member) Registration number of company, enterprise, 2.4 close corporation, partnership agreement or trust 2.5 Tax Reference Number: 2.6 VAT Registration Number:

The names of all directors / trustees / shareholders / members, their individual identity numbers, tax reference numbers and, if applicable, employee/PERSAL numbers must be indicated in paragraph 3 below

<ul><li>2.7 Are you or any person connected with the bidder presently employed by the state?</li><li>If so, furnish the following particulars</li></ul>	Yes	No		
<ul> <li>2.7.1 Name of person / director / trustee / shareholder / member:</li> <li>Name of state institution at which you or the person connected to the bidder is employed:</li> <li>Position occupied in the state institution:</li> </ul>				
Any other particulars				
2.7.2 If you are presently employed by the state, did you obtain the appropriate authority to undertake remunerative work outside employment in the public sector?	Yes	No		
If yes, did you attach proof of such authority to the bid document?	Yes	No		
2.7.3 If no, furnish reasons for non-submission of such proof:				
Note: Failure to submit proof of such authority, where applicable, may result in disqualification of the bid.)				

<ul> <li>2.8 Did you or your spouse, or any of the company's directors /trustees / shareholders /members or their spouses conduct business with the state in the previous twelve months?</li> <li>2.8.1 If so, furnish particulars:</li> </ul>	Yes	Νο
2.8.1 If so, furnish particulars:		
2.9 Do you, or any person with the bidder, have any relationship (family, friend, other) with person employed by the state and who ma be involved with the evaluation and or adjudication of this bid?	a	No
2.9.1 If so, furnish particulars:		
2.10 Are you, or any person connected with the bidder, aware of any relationship (family, friend, other) between any other bidder and any person employed by the state who may be involved with the evaluation and or adjudication of this bid?	Yes	Νο
2.10.1 If so, furnish particulars:		
2.11 Do you or any of the directors / trustees / shareholders / members of the company have any interest in any other related companies whether or not they are bidding for this contract?	Yes	Νο
2.11.1 If so, furnish particulars:		

<sup>1</sup>"State" means –

(a) any national or provincial department, national or provincial public entity or constitutional institution within the meaning of the Public Finance Management Act, 1999 (Act No. 1 of 1999);

(b) any municipality or municipal entity;

(c) provincial legislature;

(d) national Assembly or the national Council of provinces; or

(e) Parliament.

<sup>2</sup>"Shareholder" means a person who owns shares in the company and is actively involved in the management of the enterprise or business and exercises control over the enterprise

3 Full deta	Full details of directors/trustees/members/shareholders. (Attach schedule if space insufficient)					
Fu	ll Name	Identity Number	Personal Income Tax Reference Number	State Employee Number / Persal Number		

Certify that the information furnished in paragraphs 2 and 3 above is correct.

I accept that the state may reject the bid or act against me should this declaration prove to be false

Name of bidder	
Position	
Signature	
Date	

#### This document must be signed and submitted together with your bid

#### THE NATIONAL INDUSTRIAL PARTICIPATION PROGRAMME

#### INTRODUCTION

The National Industrial Participation (NIP) Programme, which is applicable to all government procurement contracts that have an imported content, became effective on the 1 September 1996. The NIP policy and guidelines were fully endorsed by Cabinet on 30 April 1997. In terms of the Cabinet decision, all state and parastatal purchases / lease contracts (for goods, works and services) entered into after this date, are subject to the NIP requirements. NIP is obligatory and therefore must be complied with. The Industrial Participation Secretariat (IPS) of the Department of Trade and Industry (DTI) is charged with the responsibility of administering the programme.

#### 1. PILLARS OF THE PROGRAMME

- 1.1 The NIP obligation is benchmarked on the imported content of the contract. Any contract having an imported content equal to or exceeding US\$ 10 million or other currency equivalent to US\$ 10 million will have a NIP obligation. This threshold of US\$ 10 million can be reached as follows:
  - a) Any single contract with imported content exceeding US\$10 million.
  - b) Multiple contracts for the same goods, works or services each with imported content exceeding US\$3 million awarded to one seller over a 2 year period which in total exceeds US\$10 million.
  - c) A contract with a renewable option clause, where should the option be exercised the total value of the imported content will exceed US\$10 million.
  - d) Multiple suppliers of the same goods, works or services under the same contract, where the value of the imported content of each allocation is equal to or exceeds US\$ 3 million worth of goods, works or services to the same government institution, which in total over a two (2) year period exceeds US\$10 million.
- 1.2 The NIP obligation applicable to suppliers in respect of sub-paragraphs 1.1 (a) to 1.1 (c) above will amount to 30% of the imported content whilst suppliers in respect of paragraph 1.1 (d) shall incur 30% of the total NIP obligation on a *pro-rata* basis.
- 1.3 To satisfy the NIP obligation, the DTI would negotiate and conclude agreements such as investments, joint ventures, sub-contracting, licensee production, export promotion, sourcing arrangements and research and development (R&D) with partners or suppliers.
- 1.4 A period of seven years has been identified as the time frame within which to discharge the obligation.

#### 2 REQUIREMENTS OF THE DEPARTMENT OF TRADE AND INDUSTRY

- 2.1 In order to ensure effective implementation of the programme, successful bidders (contractors) are required to, immediately after the award of a contract that is in excess of R10 million (ten million Rands), submit details of such a contract to the DTI for reporting purposes.
- 2.2 The purpose for reporting details of contracts in excess of the amount of R10 million (ten million Rands) is to cater for multiple contracts for the same goods, works or services; renewable contracts and multiple suppliers for the same goods, works or services under the same contract as provided for in paragraphs 1.1.(b) to 1.1. (d) above.

# 3 BID SUBMISSION AND CONTRACT REPORTING REQUIREMENTS OF BIDDERS AND SUCCESSFUL BIDDERS (CONTRACTORS)

- 3.1 Bidders are required to sign and submit this Standard Bidding Document (SBD 5) together with the bid on the closing date and time.
- 3.2 In order to accommodate multiple contracts for the same goods, works or services; renewable contracts and multiple suppliers for the same goods, works or services under the same contract as indicated in sub-paragraphs 1.1 (b) to 1.1 (d) above and to enable the DTI in determining the NIP obligation, successful bidders (contractors) are required, immediately after being officially notified about any successful bid with a value in excess of R10 million (ten million Rands), to contact and furnish the DTI with the following information:
  - Bid/contract number.
  - Description of the goods works or services.
  - Date on which the contract was accepted.
  - Name, address and contact details of the government institution.
  - Value of the contract.
  - Imported content of the contract, if possible.
- 3.3 The information required in paragraph 3.2 above must be sent to the Department of Trade and Industry, Private Bag X84, Pretoria, 0001 for the attention of Mr Elias Malapane within five (5) working days after award of the contract. for further details about the programme, contact Ms R Muthan on telephone (012) 394 1288, Mobile (066) 301 2051 or e-mail at <u>amuthan@thedtic.gov.za</u>.

#### 4 PROCESS TO SATISFY THE NIP OBLIGATION

- 4.1 Once the successful bidder (contractor) has made contact with and furnished the DTI with the information required, the following steps will be followed:
  - a) the contractor and the DTI will determine the NIP obligation;
  - b) the contractor and the DTI will sign the NIP obligation agreement;
  - c) the contractor will submit a performance guarantee to the DTI;
  - d) the contractor will submit a business concept for consideration and approval by the DTI;
  - e) upon approval of the business concept by the DTI, the contractor will submit detailed business plans outlining the business concepts;
  - f) the contractor will implement the business plans; and
  - g) the contractor will submit bi-annual progress reports on approved plans to the DTI.
- 4.2 The NIP obligation agreement is between the DTI and the successful bidder (contractor) and, therefore, does not involve the purchasing institution.

Bid number	Closing date:	
Name of bidder		
Postal Address		
	Postal Code	
Name in print		
Position		
Signature:	Date:	

#### DECLARATION OF BIDDER'S PAST SUPPLY CHAIN MANAGEMENT PRACTICES

- 1 This Standard Bidding Document must form part of all bids invited.
- 2 It serves as a declaration to be used by institutions in ensuring that when goods and services are being procured, all reasonable steps are taken to combat the abuse of the supply chain management system.
- 3 The bid of any bidder may be disregarded if that bidder or any of its directors have- a) abused the institution's supply chain management system;
  - b) committed fraud or any other improper conduct in relation to such system; or
  - c) failed to perform on any previous contract.

# 4 In order to give effect to the above, the following questionnaire must be completed and submitted with the bid.

Item	Question	Yes	No
4.1	Is the bidder or any of its directors listed on the National Treasury's Database of Restricted Suppliers as companies or persons prohibited from doing business with the public sector? (Companies or persons who are listed on this Database were informed in writing of this restriction by the Accounting Officer/Authority of the institution that imposed the restriction after the <u>audi alteram partem</u> rule was applied). The Database of Restricted Suppliers now resides on the National Treasury's website (www.treasury.gov.za) and can be accessed by clicking on its link at the bottom of the home page.		
4.1.1	If so, furnish particulars:		
4.2	Is the bidder or any of its directors listed on the Register for Tender Defaulters in terms of section 29 of the Prevention and Combating of Corrupt Activities Act (No 12 of 2004)? Register for Tender Defaulters can be accessed on the National Treasury's website (www.treasury.gov.za) by clicking on its link at the bottom of the home page.		
4.2.1	If so, furnish particulars:		

#### SBD8

4.3	Was the bidder or any of its directors convicted by a court of law (including a court outside of the Republic of South Africa) for fraud or corruption during the past five years?					
4.3.1	If so, furnish particulars:					
4.4	Was any contract between the bidder and any organ of state terminated during the past five years on account of failure to perform on or comply with the contract?					
4.4.1	If so, furnish particulars:					
	Certification					
I, the	undersigned					

certify that the information furnished on this declaration form is true and correct. I accept that, in addition to cancellation of a contract, action may be taken against me should this declaration prove to be false.

I accept that the state may reject the bid or act against me should this declaration prove to be false.

Name of bidder:		
Position:		
Signature:	Date	

#### CERTIFICATE OF INDEPENDENT BID DETERMINATION

- 1. This Standard Bidding Document (SBD) must form part of all bids<sup>1</sup> invited.
- 2. Section 4 (1) (b) (iii) of the Competition Act No. 89 of 1998, as amended, prohibits an agreement between, or concerted practice by, firms, or a decision by an association of firms, if it is between parties in a horizontal relationship and if it involves collusive bidding (or bid rigging).<sup>2</sup> Collusive bidding is a *pe se* prohibition meaning that it cannot be justified under any grounds.

<sup>1</sup> Includes price quotations, advertised competitive bids, limited bids and proposals.

<sup>2</sup> Bid rigging (or collusive bidding) occurs when businesses, that would otherwise be expected to compete, secretly conspire to raise prices or lower the quality of goods and / or services for purchasers who wish to acquire goods and / or services through a bidding process. Bid rigging is, therefore, an agreement between competitors not to compete

- 3. Treasury Regulation 16A9 prescribes that accounting officers and accounting authorities must take all reasonable steps to prevent abuse of the supply chain management system and authorizes accounting officers and accounting authorities to:
  - a. disregard the bid of any bidder if that bidder, or any of its directors have abused the institution's supply chain management system and or committed fraud or any other improper conduct in relation to such system.
  - b. cancel a contract awarded to a supplier of goods and services if the supplier committed any corrupt or fraudulent act during the bidding process or the execution of that contract.
- 4. This SBD serves as a certificate of declaration that would be used by institutions to ensure that, when bids are considered, reasonable steps are taken to prevent any form of bid rigging.
- 5. In order to give effect to the above, the attached Certificate of Bid Determination (SBD9) must be completed and submitted with the bid:

#### CERTIFICATE OF INDEPENDENT BID DETERMINATION

I, the undersigned, in submitting the accompanying bid....., in response to the invitation for the bid made by the Department Of Health, do hereby make the following statements that I certify to be true and complete in every respect:

I certify, on behalf of

that

- 1. I have read and I understand the contents of this Certificate;
- 2. I understand that the accompanying bid will be disqualified if this Certificate is found not to be true and complete in every respect;
- 3. I am authorised by the bidder to sign this Certificate, and to submit the accompanying bid, on behalf of the bidder;
- 4. Each person whose signature appears on the accompanying bid has been authorised by the bidder to determine the terms of, and to sign the bid, on behalf of the bidder;

- 5. For the purposes of this Certificate and the accompanying bid, I understand that the word "competitor" shall include any individual or organization, other than the bidder, whether or not affiliated with the bidder, who:
  - a. has been requested to submit a bid in response to this bid invitation;
  - b. could potentially submit a bid in response to this bid invitation, based on their qualifications, abilities or experience; and
  - c. provides the same goods and services as the bidder and/or is in the same line of business as the bidder.
- 6. The bidder has arrived at the accompanying bid independently from, and without consultation, communication, agreement or arrangement with any competitor. However communication between partners in a joint venture or consortium<sup>3</sup> will not be construed as collusive bidding.
- 7. In particular, without limiting the generality of paragraphs 6 above, there has been no consultation, communication, agreement or arrangement with any competitor regarding:
  - a. prices;
  - b. geographical area where product or service will be rendered (market allocation)
  - c. methods, factors or formulas used to calculate prices;
  - d. the intention or decision to submit or not to submit, a bid;
  - e. the submission of a bid which does not meet the specifications and conditions of the bid; or
  - f. bidding with the intention not to win the bid.
- 8. In addition, there have been no consultations, communications, agreements or arrangements with any competitor regarding the quality, quantity, specifications and conditions or delivery particulars of the products or services to which this bid invitation relates.
- 9. The terms of the accompanying bid have not been, and will n ot be, disclosed by the bidder, directly or indirectly, to any competitor, prior to the date and time of the official bid opening or of the awarding of the contract.
- 10. I am aware that, in addition and without prejudice to any other remedy provided to combat any restrictive practices related to bids and contracts, bids that are suspicious will be reported to the Competition Commission for investigation and possible imposition of administrative penalties in terms of section 59 of the Competition Act No 89 of 1998 and or may be reported to the National Prosecuting Authority (NPA) for criminal investigation and or may be restricted from conducting business with the public sector for a period not exceeding ten (10) years in terms of the Prevention and Combating of Corrupt Activities Act No 12 of 2004 or any other applicable legislation.

Name of Bidder		
Full Name		
Postion		
Signature	Date	

<sup>3</sup> Joint venture or Consortium means an association of persons for the purpose of combining their expertise, property, capital, efforts, skill and knowledge in an activity for the execution of a contract.



#### **AUTHORISATION DECLARATION (PBD1)**

NAME OF THE BIDDER				
Are you sourcing the produ	cts from a third party?	Yes	No	

\* If you have answered YES to the above question, please provide full details in the table below of the third party (ies) from whom you are sourcing the products.

 Declaration by the bidder where the bidder is sourcing the products from a third party. The bidder hereby declares the following:-

- 1.1 The bidder is sourcing the products listed in the PBD1.1 attached, from a third party in order to comply with the terms and conditions of the bid.
- 1.2 The bidder has informed the third party of the terms and conditions of the bid and the third party is acquainted with the said terms and the description of the products listed in the PBD1.1.
- 1.3 The bidder has received the attached, unconditional written undertaking from the third party to supply the products listed in the PBD1.1 in accordance with the terms and conditions of the bid document for the duration of the contract. A template has been attached (PBD1.2) that is to be used for the purpose of the third party undertaking.
- 1.4 The bidder confirms that all f inancial and supply arrangements for the products have been mutually agreed upon between the bidder and the third party.
- 2. The bidder declares that the information contained herein is true and correct.
- 3. The bidder acknowledges that the Department of Health reserves the right to verify the information contained therein and if found to be false or incorrect may invoke any remedies available to it in the bid documents.

Signed at	on the	day of	
Full Names			
Designation			
Signature			

PBD1

### List of the products offered sourced from third party

Bid Item No	Brand Name	Name of the company from where the products will be sourced	Address and contact details of the company from where the products will be sourced

List of the products offered sourced from third party - continued

Bid Item No	Brand Name	Name of the company from where the products will be sourced	Address and contact details of the company from where the products will be sourced

(Should the table provided not be sufficient for all the items offered, please provide additional information as an attachment and it must be properly referenced to this document)

PBD1.1

Template for unconditional written undertaking from the third party				
Note:				
The authorisation le	tter must be on the official letterhead of the third p	party		
A separate letter mu	ist be included for each third party			
The authorisation le	tter must be addressed to the Bidding Company			
Name of Bidding Co	mpany:			
Address of Bidding	Company:			
Attention:				
Dear Sir/Madam				
AUTHORISATION	ETTER: CONTRACT NO	_		
We,	(Na	nme of Third Party)		
hereby authorise yo	u,(Na	ame of Company) to include the		
products listed below	w in your bid submission for the abovementioned	contract.		
We confirm that we	have firm supply arrangements in place, and ha	we familiarised ourselves with the		
item descriptions, s	pecifications and bid conditions relating to item/s I	isted below.		
ltem no.	Description of product	Brand name		

(Should the table provided not be sufficient for all the items offered, please provide additional information as an attachment and it must be properly referenced to this document)

Yours faithfully,

Signature of the Third Party:

Date:

#### PBD5

#### PBD5 DECLARATION OF COMPLIANCE WITH GOOD MANUFACTURING PRACTICE (GMP)

To be signed by the Chief Executive Officer of the Company in terms of this bid.

l,.....

(Full name) being the Chief Executive Officer

Of.....

(Organisation name) hereby certify that to the best of my knowledge all reasonable steps have been taken to ensure that:

- a) There are no outstanding or impending GMP or legal matters that may have a material impact on the Company's ability to perform in terms of this contract.
- b) In terms of this declaration, I undertake to inform the Department of Health at first knowledge of any circumstances that may result in interrupted supply.
- c) (Organisation name)...... has complied with all the legal requirements as stipulated in terms of Medicines and Related Substances Act 101 of 1965, as amended,: for such products offered.

Full Name of Chief Executive Officer

.....

Full Identity Number/or equivalent of the Chief Executive Officer

.....

Signature of Chief Executive Officer

.....

Signature of Witness

.....

Signed at

Date

#### PBD 8: DECLARATION OF COMPLIANCE WITH THE SPECIAL REQUIREMENTS AND CONDITIONS OF CONTRACT

#### To be signed by the Chief Executive Officer of the Company in terms of this bid.

I,..... (Full name) being the Chief Executive Officer

of.....(Organisation name) hereby declare that to the best of my knowledge all reasonable steps have been taken to ensure that:

- a) (Organisation name)...... has complied with all the legal requirements as provided in the Medicines and Related Substances Act 101 of 1965, as amended, for such products offered;
- b) There are no outstanding or impending matters (including GMP or legal) that may have a material impact on the Company's ability to perform in terms of this contract

In terms of this declaration, I undertake to inform the Department of Health at first knowledge of any circumstances that may result in interrupted supply of product if the contract is awarded.

I further declare that .....(Organisation name) will comply with the requirements and conditions as stipulated in the Special Requirements and Conditions of Contract

Full Name of Chief Executive Officer
Full Identity Number/or equivalent of the Chief Executive Officer
Signature of Chief Executive Officer
Signature of Witness
Date Signed at

Definition of fields in Bid Response Document, to be read in conjunction with the Special Requirements and Conditions of Contract

Field Name	Field Definition
	DS WHICH ARE PRE-FILLED AND MAY NOT BE ALTERED
Item Number	The relevant item number which will be used throughout the contract period. Each item number is linked to a specification
Item Specification	The specification of the item for which a call for bids has been issued, as linked to the item number.
Unit	The unit of measure for the specification. This determines how the estimates are expressed and how the price should be quoted. This may be one injection or one pack of 100 tablets, etc.
Estimate	The estimated quantities associated with the item number and specification, for the full contract period. Estimates are expressed in unit packs.
FIELDS WHICH ARE T	O BE COMPLETED BY THE BIDDER FOR ALL ITEMS ON WHICH BIDS ARE OFFERED
Registered legal name of bidder	The full, registered, legal name of the bidder, as on VAT registration certificate and Medicine Registration Certificate applicant.
Quantity for full period	The volume of the item (expressed in units) which the bidder can provide during the complete period of the tender
Delivered price in ZAR	Final price offered by a bidder for an item number as per specification, which includes VAT and delivery. <b>Must be the price for a unit as advertised</b> .
Registered Product Name	Brand name. Must correspond with Medicine Registration Certificate (1) GW12/7
Conforms to specification?	Confirm whether or not the product on offer conforms exactly to the Item Specification.
If <b>NO</b> : Detail deviation from specification.	Detail exact deviation from Item Specification, as per registration of product on offer.
Product Registration Number	As per Medicine Registration Certificate Certificate(2) GW12/7
License to Manufacture Medicines: License Number , Expiry date	As per License to Manufacture Medicines – this must correspond with the document submitted
Pack Size Offered: Unit pack	Single unit offered according to specification in numbers e.g. each (1) This must correspond with the delivered price.
Pack Size Offered: Shelf Pack	Number of Unit Packs within the smallest wrap (e.g. 10 ampoules)
Standard units in: Shipper Pack	Number of unit packs in a shipper / bulk box
Lead-Time	Interval between receipt of an order until delivery at facility which placed the order. Must not exceed 14 calendar days.
Initial lead time	Interval between award of the tender and ability to fill an order. This must not exceed 75 calendar days.
Minimum Order Quantity	The lowest acceptable quantity for a given purchase order.
Batch size for the bid item, in number of packs	Batch size, expressed in number of units
Monthly batch capacity	Monthly batch capacity that will be assigned for the bid item for the duration of the contract expressed in number of batches.
Technical amendment required?	Do you require a technical amendment to perform according to the conditions of your bid Y/N
If YES: Provide details	Provide all relevant details (can be provided in a covering letter)

Definition of fields in Bid Response Document, to be read in conjunction with the Special Requirements and Conditions of Contract

Field Name         Field Definition           EAN 13 Barcode for Unit Pack         Provide Number           EAN 13 Barcode for Shelf Pack         Provide Number           EAN 13 Barcode for Shiper Pack         Provide Number           TF14 Barcode for Shiper Pack         Provide Number           DBarcode or Similar         Provide Number           NAPPI Code         Provide Code           Manufacturer         As per MCC Certificate (8) GW12/7 - List all sources           SEP Price         The most recently approved Single Exit Price expressed in corresponding unit to bid           Are any of the listed manufacturers etc. 3rd parties to the bidder?         YiN           API Source Full Site Name         Full name of API source, including company name and site - List all sources           API Source Full Address         Full physical address of API source - List all sources           API Source Country         Country of API source - List all sources           API Source Country         Country of API source - List all sources           API Source Country         The procentage of the Delivered product, the component may be reflected as part of formulation cost.           Procentage of Delivered Price attributable to API         The procentage of the Delivered price associated with API, (the therapeutically active component of the medicine). Should an item be imported as finished product, the component attributable to incorder expenditure	Conditions of Contract				
Pack         Image: Provide Number           EAN 13 Barcode for Shilpper Pack         Provide Number           ITF14 Barcode for Shipper Pack         Provide Number           2D Barcode or Similar         Provide Number           ARPPI Code         Provide Code           Manufacturer         As per MCC Certificate (8) GW12/7 – List all sources           SEP Price         The most recently approved Single Exit Price expressed in corresponding unit to bid           Are any of the listed manufacturers         Y/N           etc. 3rd parties to the bidder?         If YES - complete PBD1 and include letter(s) of authorisation as applicable           API Source Full Site Name         Full name of API source – List all sources           API Source Country         Country of API source – List all sources           API Source Country         Country of API source – List all sources           API Source Country         Country of API source – List all sources           Net: VAT must be apportioned equally across all components. Please see pricing section in Special Conditions           Price attributable to API         The percentage of the Delivered Price associated with API, (the threapeutically across all component attributable to imported expenditure           Price attributable to API         Portion of API component attributable to imported expenditure           Price attributable to API         Portion of Formulation component attributable to	Field Name	Field Definition			
Pack         International second		Provide Number			
Pack         Provide Number           NAPPI Code         Provide Code           Manufacturer         As per MCC Certificate (8) GW12/7 – List all sources           SEP Price         The most recently approved Single Exit Price expressed in corresponding unit to bid           Are any of the listed manufacturers etc. 3rd parties to the bidder?         Y/N           API Source Full Site Name (x3)         Full name of API source, including company name and site – List all sources           API Source Full Address         Full physical address of API source – List all sources           API Source Country         Country of API source – List all sources           API Source Contact         Listed contact information           Price attributable to API         Proton of API source of the Delivered Price associated with API, (the therapeutically across all component s. Please see pricing section in Special Conditions           Percentage of Delivered Price attributable to imported as part of formulation (includes all operations in the process of which different chemical substances, including the API, are combined to produce a final medicinal product, includes material, processing, production, quality assurance and related controls.           Local (Formulation         Portion of Formulation component attributable to local expenditure           Price attributable to Imported (API)         Portion of Formulation component attributable to local expenditure           Price attributable to Portion of Formulation component attributable to imported expenditure		Provide Number			
NAPPI Code         Provide Code           Manufacturer         As per MCC Certificate (8) GW12/7 – List all sources           SEP Price         The most recently approved Single Exit Price expressed in corresponding unit to bid           Are any of the listed manufacturers etc. 3rd parties to the bidder?         Y/N           If YES - complete PBD1 and include letter(s) of authorisation as applicable etc. 3rd parties to the bidder?         Full name of API source, including company name and site – List all sources           API Source Full Site Name (x3)         Full physical address of API source – List all sources           API Source Country         Country of API source – List all sources           API Source Country         Country of API source – List all sources           API Source Contact         Listed contact information           Price attributable to API         PRICING COMPONENT BREAKDOWN           Note: VAT must be apportioned equally across all components. Please see pricing section in Special Conditions           Price attributable to API         Protion of API component attributable to imported expenditure           Price attributable to API         Portion of API component attributable to imported expenditure           Price attributable to         Portion of Formulation component attributable to insoled an includes all operations in the process of which different chemical substances, including the API, are combined to produce a final medicinal product), includes material, processing, production, quality assurance and relat		Provide Number			
Manufacturer         As per MCC Certificate (8) GW12/7 – List all sources           SEP Price         The most recently approved Single Exit Price expressed in corresponding unit to bid           Are any of the listed manufacturers etc. 3rd parties to the bidder?         Y/N           API Source Full Site Name (x3)         Full name of API source , including company name and site – List all sources           API Source Full Address         Full physical address of API source – List all sources           API Source Country         Country of API source – List all sources           API Source Contact         Listed contact information           Note: VAT must be apportioned equally across all components. Please see pricing section in Special Conditions           Percentage of Delivered Price attributable to API         Portion of API component attributable to imported as finished product, the component attributable to imported expenditure           Percentage of Delivered Price attributable to Formulation         Portion of API component attributable to imported expenditure           Price attributable to Formulation         Portion of Formulation component attributable to imported expenditure           Price attributable to Formulation         Portion of Formulation component attributable to local expenditure           Packaging         Portion of Formulation component attributable to local expenditure           Price attributable to Formulation         Portion of Formulation component attributable to local expenditure	2D Barcode or Similar	Provide Number			
SEP Price         The most recently approved Single Exit Price expressed in corresponding unit to bid           Are any of the listed manufacturers etc. 3rd parties to the bidder?         Y/N           API Source Full Site Name (x3)         Full name of API source, including company name and site – List all sources           API Source Full Address         Full name of API source – List all sources           API Source Country         Country of API source – List all sources           API Source Country         Country of API source – List all sources           API Source Contact         Listed contact information           Pricing ComPonent BREAKDOWN         Note: VAT must be apportioned equally across all components. Please see pricing section in Special Conditions           Percentage of Delivered Price attributable to API         Portion of API component attributable to imported as finished product, the component attributable to imported expenditure           Percentage of Delivered Price attributable to Formulation         Portion of API component attributable to imported expenditure           Processing, production, quality assurance and related controls.         Portion of Formulation component attributable to imported expenditure           Processing, production, quality assurance and related controls.         Portion of Formulation component attributable to local expenditure           Procentage of Delivered Price attributable to Formulation         Portion of Formulation component attributable to local expenditure           Procenta	NAPPI Code	Provide Code			
SEP Price         bid           Are any of the listed manufacturers etc. 3rd parties to the bidder?         Y/N           API Source Full Site Name (x3)         YII ame of API source, including company name and site – List all sources           API Source Full Address         Full name of API source – List all sources           API Source Country         Country of API source – List all sources           API Source Contact         Listed contact information           Price attributable to API         PRICING COMPONENT BREAKDOWN           Note: VAT must be apportioned equally across all components. Please see pricing section in Special Conditions           Percentage of Delivered Price attributable to API         The percentage of the Delivered Price associated with API, (the therapeutically active component of the medicine). Should an item be imported as finished product, the component attributable to imported as finished product, the component attributable to imported aspenditure           Percentage of Delivered Price attributable to Formulation         Portion of API component attributable to imported expenditure           Percentage of Delivered Price attributable to Formulation         Portion of Formulation component attributable to local expenditure           Imported (API)         Portion of Formulation component attributable to local expenditure           Imported (Formulation)         Portion of Formulation component attributable to local expenditure           Pare excessing, production, quality assurance and related controls.         <	Manufacturer	As per MCC Certificate (8) GW12/7 – List all sources			
manufacturers etc. 3rd parties to the bidder?If YES - complete PBD1 and include letter(s) of authorisation as applicable bidder?API Source Full Site Name (x3)Full name of API source, including company name and site – List all sourcesAPI Source Full AddressFull physical address of API source – List all sourcesAPI Source CountryCountry of API source – List all sourcesAPI Source ContactListed contact informationPRICING COMPONENT BREAKDOWNNote: VAT must be apportioned equally across all components. Please see pricing section in Special ConditionsPercentage of Delivered Price attributable to APIThe percentage of the Delivered Price associated with API, (the therapeutically active component of the medicine). Should an item be imported as finished product, the component attributable to imported expenditurePercentage of Delivered Price attributable to APIPortion of API component attributable to imported expenditurePercentage of Delivered Price attributable toPortion of API component attributable to imported expenditurePercentage of Delivered Price attributable toPortion of Formulation component attributable to local expenditurePercentage of Delivered Price attributable to Imported (Formulation)Portion of Formulation component attributable to local expenditureImported (Formulation)Portion of Packaging component attributable to local expenditureProceatingPortion of Packaging component attributable to local expenditureImported (Formulation)Portion of Packaging component attributable to local expenditureProceatingPortion of Packaging component attribut	SEP Price				
(X3)Full physical address of API source – List all sourcesAPI Source Full AddressFull physical address of API source – List all sourcesAPI Source CountryCountry of API source – List all sourcesAPI Source ContactListed contact informationPRICING COMPONENT BREAKDOWNNote: VAT must be apportioned equally across all components. Please see pricing section in Special ConditionsPercentage of Delivered Price attributable to APIThe percentage of the Delivered price associated with API, (the therapeutically active component of the medicine). Should an item be imported as finished product, the component may be reflected as part of formulation cost.Percentage of Delivered Price attributable to FormulationPortion of API component attributable to imported expenditurePercentage of Delivered Price attributable to FormulationPortion of API component attributable to imported expenditurePercentage of Delivered Price attributable to FormulationPortion of Formulation component attributable to includes all operations in the process of which different chemical substances, including the API, are combined to produce a final medicinal product), includes material, processing, production, quality assurance and related controls.Local (Formulation)Portion of Formulation component attributable to inported expenditurePackagingPortion of Packaging component attributable to local expenditurePackagingPortion of Packaging component attributable to local expenditureImported (Formulation)Portion of Packaging component attributable to local expenditureLocal (Packaging)Portion of Packaging component attributable to	manufacturers etc. 3rd parties to the				
API Source Country         Country of API source – List all sources           API Source Contact         Listed contact information           Note: VAT must be apportioned equality across all components. Please see pricing section in Special Conditions           Percentage of Delivered Price attributable to API         The percentage of the Delivered Price associated with API, (the therapeutically active component of the medicine). Should an item be imported as finished product, the component may be reflected as part of formulation cost.           Imported (API)         Portion of API component attributable to imported expenditure           Percentage of Delivered Price attributable to Formulation         The percentage of the delivered price associated with Formulation, (includes all operations in the process of which different chemical substances, including the API, are combined to produce a final medicinal product), includes material, processing, production, quality assurance and related controls.           Local (Formulation)         Portion of Formulation component attributable to local expenditure           Packaging         The percentage of the Delivered Price associated with Packaging, where packaging includes all operations in the process of packaging medicine into primary and/or secondary packaging, packaging material and labels.           Local (Packaging)         Portion of Packaging component attributable to local expenditure           Imported (Packaging)         Portion of Packaging component attributable to inported expenditure           Local (Packaging)         Portion of Packaging component attributable to inported expenditur		Full name of API source, including company name and site – List all sources			
API Source Contact         Listed contact information <b>PRICING COMPONENT BREAKDOWN</b> Note: VAT must be apportioned equally across all components. Please see pricing section in Special Conditions           Percentage of Delivered Price attributable to API         The percentage of the Delivered Price associated with API, (the therapeutically active component of the medicine). Should an item be imported as finished product, the component may be reflected as part of formulation cost.           Imported (API)         Portion of API component attributable to imported expenditure           Percentage of Delivered Price attributable to Formulation         The percentage of the delivered price associated with Formulation, (includes all operations in the process of which different chemical substances, including the API, are combined to produce a final medicinal product), includes material, processing, production, quality assurance and related controls.           Local (Formulation)         Portion of Formulation component attributable to local expenditure           Imported (Formulation)         Portion of Formulation component attributable to imported expenditure           Packaging         The percentage of the Delivered Price associated with Packaging, where packaging includes all operations in the process of packaging medicine into primary and/or secondary packaging, packaging material and labels.           Local (Packaging)         Portion of Packaging component attributable to local expenditure           Imported (Packaging)         Portion of Packaging component attributable to imported expenditure	API Source Full Address	Full physical address of API source – List all sources			
PRICING COMPONENT BREAKDOWNNote: VAT must be apportioned equally across all components. Please see pricing section in Special ConditionsPercentage of Delivered Price attributable to APIThe percentage of the Delivered Price associated with API, (the therapeutically active component of the medicine). Should an item be imported as finished product, the component may be reflected as part of formulation cost.Imported (API)Portion of API component attributable to imported expenditurePercentage of Delivered Price attributable to FormulationThe percentage of the delivered price associated with Formulation, (includes all operations in the process of which different chemical substances, including the API, are combined to produce a final medicinal product), includes material, processing, production, quality assurance and related controls.Local (Formulation)Portion of Formulation component attributable to local expenditureImported (Formulation)Portion of Formulation component attributable to imported expenditurePackagingThe percentage of the Delivered Price associated with Packaging, where packaging includes all operations in the process of packaging medicine into primary and/or secondary packaging, packaging material and labels.Local (Packaging)Portion of Packaging component attributable to insported expenditureImported (Packaging)Portion of Packaging component attributable to insported expenditureLocal (Packaging)Portion of Packaging component attributable to local expenditureLocal (Packaging)Portion of Packaging component attributable to insported expenditureLogisticsPercentage of delivered price associated with logistics, where log	API Source Country	Country of API source – List all sources			
Note: VAT must be apportioned equally across all components. Please see pricing section in Special ConditionsPercentage of Delivered Price attributable to APIThe percentage of the Delivered Price associated with API, (the therapeutically active component of the medicine). Should an item be imported as finished product, the component may be reflected as part of formulation cost.Imported (API)Portion of API component attributable to imported expenditurePercentage of Delivered Price attributable to FormulationThe percentage of the delivered price associated with Formulation, (includes all operations in the process of which different chemical substances, including the API, are combined to produce a final medicinal product), includes material, processing, production, quality assurance and related controls.Local (Formulation)Portion of Formulation component attributable to local expenditurePackagingPortion of Formulation component attributable to imported expenditurePackagingPortion of Packaging component attributable to local expenditureImported (Packaging)Portion of Packaging component attributable to local expenditureImported (Packaging)Portion of Packaging component attributable to local expenditureLocal (Packaging)Portion of Packaging component attributable to imported expenditureLogisticsPercentage of delivered price associated with logistics, where logistics includes all operations, taking place within the Republic of South Africa, relating to the storage, distribution and transportation of medicine to the healthcare facility or pharmaceutical depot.Gross MarginPercentage of delivered price not associated with API, Formulation, Packaging, or Logistics. <td>API Source Contact</td> <td>Listed contact information</td>	API Source Contact	Listed contact information			
Price attributable to APIactive component of the medicine). Should an item be imported as finished product, the component may be reflected as part of formulation cost.Imported (API)Portion of API component attributable to imported expenditurePercentage of Delivered Price attributable to FormulationThe percentage of the delivered price associated with Formulation, (includes all operations in the process of which different chemical substances, including the API, are combined to produce a final medicinal product), includes material, processing, production, quality assurance and related controls.Local (Formulation)Portion of Formulation component attributable to local expenditureImported (Formulation)Portion of Formulation component attributable to imported expenditurePackagingThe percentage of the Delivered Price associated with Packaging, where packaging includes all operations in the process of packaging medicine into primary and/or secondary packaging, packaging material and labels.Local (Packaging)Portion of Packaging component attributable to local expenditureImported (Packaging)Portion of Packaging component attributable to imported expenditureLocal (Packaging)Portion of Packaging component attributable to local expenditureImported (Packaging)Portion of Packaging component attributable to imported expenditureLogisticsPercentage of delivered price associated with logistics, where logistics includes all operations, taking place within the Republic of South Africa, relating to the storage, distribution and transportation of medicine to the healthcare facility or pharmaceutical depot.Gross MarginPercentage of delivered price not associated with API, For					
Percentage of Delivered Price attributable to FormulationThe percentage of the delivered price associated with Formulation, (includes all operations in the process of which different chemical substances, including the API, are combined to produce a final medicinal product), includes material, processing, production, quality assurance and related controls.Local (Formulation)Portion of Formulation component attributable to local expenditureImported (Formulation)Portion of Formulation component attributable to imported expenditurePackagingThe percentage of the Delivered Price associated with Packaging, where packaging includes all operations in the process of packaging medicine into primary and/or secondary packaging, packaging material and labels.Local (Packaging)Portion of Packaging component attributable to local expenditureImported (Packaging)Portion of Packaging component attributable to local expenditureLogisticsPercentage of delivered price associated with logistics, where logistics includes all operations, taking place within the Republic of South Africa, relating to the storage, distribution and transportation of medicine to the healthcare facility or pharmaceutical depot.Gross MarginPercentage of delivered price not associated with API, Formulation, Packaging, or Logistics.	Percentage of Delivered Price attributable to API	active component of the medicine). Should an item be imported as finished			
Price attributable to Formulationoperations in the process of which different chemical substances, including the API, are combined to produce a final medicinal product), includes material, processing, production, quality assurance and related controls.Local (Formulation)Portion of Formulation component attributable to local expenditureImported (Formulation)Portion of Formulation component attributable to imported expenditurePackagingThe percentage of the Delivered Price associated with Packaging, where packaging includes all operations in the process of packaging medicine into primary and/or secondary packaging, packaging material and labels.Local (Packaging)Portion of Packaging component attributable to local expenditureImported (Packaging)Portion of Packaging component attributable to local expenditureLogisticsPercentage of delivered price associated with logistics, where logistics includes all operations, taking place within the Republic of South Africa, relating to the 	Imported (API)	Portion of API component attributable to imported expenditure			
Imported (Formulation)Portion of Formulation component attributable to imported expenditurePackagingThe percentage of the Delivered Price associated with Packaging, where packaging includes all operations in the process of packaging medicine into primary and/or secondary packaging, packaging material and labels.Local (Packaging)Portion of Packaging component attributable to local expenditureImported (Packaging)Portion of Packaging component attributable to imported expenditureLogisticsPercentage of delivered price associated with logistics, where logistics includes all operations, taking place within the Republic of South Africa, relating to the storage, distribution and transportation of medicine to the healthcare facility or pharmaceutical depot.Gross MarginPercentage of delivered price not associated with API, Formulation, Packaging, or Logistics.	Price attributable to	operations in the process of which different chemical substances, including the API, are combined to produce a final medicinal product), includes material,			
PackagingThe percentage of the Delivered Price associated with Packaging, where packaging includes all operations in the process of packaging medicine into primary and/or secondary packaging, packaging material and labels.Local (Packaging)Portion of Packaging component attributable to local expenditureImported (Packaging)Portion of Packaging component attributable to imported expenditureLogisticsPercentage of delivered price associated with logistics, where logistics includes all operations, taking place within the Republic of South Africa, relating to the storage, distribution and transportation of medicine to the healthcare facility or pharmaceutical depot.Gross MarginPercentage of delivered price not associated with API, Formulation, Packaging, or Logistics.	Local (Formulation)	Portion of Formulation component attributable to local expenditure			
packaging includes all operations in the process of packaging medicine into primary and/or secondary packaging, packaging material and labels.Local (Packaging)Portion of Packaging component attributable to local expenditureImported (Packaging)Portion of Packaging component attributable to imported expenditureLogisticsPercentage of delivered price associated with logistics, where logistics includes all operations, taking place within the Republic of South Africa, relating to the storage, distribution and transportation of medicine to the healthcare facility or pharmaceutical depot.Gross MarginPercentage of delivered price not associated with API, Formulation, Packaging, or Logistics.	Imported (Formulation)	Portion of Formulation component attributable to imported expenditure			
Imported (Packaging)Portion of Packaging component attributable to imported expenditureLogisticsPercentage of delivered price associated with logistics, where logistics includes all operations, taking place within the Republic of South Africa, relating to the storage, distribution and transportation of medicine to the healthcare facility or pharmaceutical depot.Gross MarginPercentage of delivered price not associated with API, Formulation, Packaging, or Logistics.	Packaging	packaging includes all operations in the process of packaging medicine into			
LogisticsPercentage of delivered price associated with logistics, where logistics includes all operations, taking place within the Republic of South Africa, relating to the storage, distribution and transportation of medicine to the healthcare facility or pharmaceutical depot.Gross MarginPercentage of delivered price not associated with API, Formulation, Packaging, or Logistics.	Local (Packaging)	Portion of Packaging component attributable to local expenditure			
all operations, taking place within the Republic of South Africa, relating to the storage, distribution and transportation of medicine to the healthcare facility or pharmaceutical depot.         Gross Margin       Percentage of delivered price not associated with API, Formulation, Packaging, or Logistics.	Imported (Packaging)	Portion of Packaging component attributable to imported expenditure			
or Logistics.	Logistics	all operations, taking place within the Republic of South Africa, relating to the storage, distribution and transportation of medicine to the healthcare facility or			
Currency Primary currency in which manufacturer trades for imported components	Gross Margin				
	Currency	Primary currency in which manufacturer trades for imported components			

# THE NATIONAL TREASURY

# **Republic of South Africa**



# **GOVERNMENT PROCUREMENT:**

# **GENERAL CONDITIONS OF CONTRACT**

July 2010

1

# **GOVERNMENT PROCUREMENT**

# GENERAL CONDITIONS OF CONTRACT July 2010

## NOTES

The purpose of this document is to:

- (i) Draw special attention to certain general conditions applicable to government bids, contracts and orders; and
- (ii) To ensure that clients be familiar with regard to the rights and obligations of all parties involved in doing business with government.

In this document words in the singular also mean in the plural and vice versa and words in the masculine also mean in the feminine and neuter.

- The General Conditions of Contract will form part of all bid documents and may not be amended.
- Special Conditions of Contract (SCC) relevant to a specific bid, should be compiled separately for every bid (if (applicable) and will supplement the General Conditions of Contract. Whenever there is a conflict, the provisions in the SCC shall prevail.

# **TABLE OF CLAUSES**

- 1. Definitions
- 2. Application
- 3. General
- 4. Standards
- 5. Use of contract documents and information; inspection
- 6. Patent rights
- 7. Performance security
- 8. Inspections, tests and analysis
- 9. Packing
- 10. Delivery and documents
- 11. Insurance
- 12. Transportation
- 13. Incidental services
- 14. Spare parts
- 15. Warranty
- 16. Payment
- 17. Prices
- 18. Contract amendments
- 19. Assignment
- 20. Subcontracts
- 21. Delays in the supplier's performance
- 22. Penalties
- 23. Termination for default
- 24. Dumping and countervailing duties
- 25. Force Majeure
- 26. Termination for insolvency
- 27. Settlement of disputes
- 28. Limitation of liability
- 29. Governing language
- 30. Applicable law
- 31. Notices
- 32. Taxes and duties
- 33. National Industrial Participation Programme (NIPP)
- 34. Prohibition of restrictive practices

#### **General Conditions of Contract**

- **1. Definitions** 1. The following terms shall be interpreted as indicated:
  - 1.1 "Closing time" means the date and hour specified in the bidding documents for the receipt of bids.
  - 1.2 "Contract" means the written agreement entered into between the purchaser and the supplier, as recorded in the contract form signed by the parties, including all attachments and appendices thereto and all documents incorporated by reference therein.
  - 1.3 "Contract price" means the price payable to the supplier under the contract for the full and proper performance of his contractual obligations.
  - 1.4 "Corrupt practice" means the offering, giving, receiving, or soliciting of any thing of value to influence the action of a public official in the procurement process or in contract execution.
  - 1.5 "Countervailing duties" are imposed in cases where an enterprise abroad is subsidized by its government and encouraged to market its products internationally.
  - 1.6 "Country of origin" means the place where the goods were mined, grown or produced or from which the services are supplied. Goods are produced when, through manufacturing, processing or substantial and major assembly of components, a commercially recognized new product results that is substantially different in basic characteristics or in purpose or utility from its components.
  - 1.7 "Day" means calendar day.
  - 1.8 "Delivery" means delivery in compliance of the conditions of the contract or order.
  - 1.9 "Delivery ex stock" means immediate delivery directly from stock actually on hand.
  - 1.10 "Delivery into consignees store or to his site" means delivered and unloaded in the specified store or depot or on the specified site in compliance with the conditions of the contract or order, the supplier bearing all risks and charges involved until the supplies are so delivered and a valid receipt is obtained.
  - 1.11 "Dumping" occurs when a private enterprise abroad market its goods on own initiative in the RSA at lower prices than that of the country of origin and which have the potential to harm the local industries in the

RSA.

- 1.12 "Force majeure" means an event beyond the control of the supplier and not involving the supplier's fault or negligence and not foreseeable. Such events may include, but is not restricted to, acts of the purchaser in its sovereign capacity, wars or revolutions, fires, floods, epidemics, quarantine restrictions and freight embargoes.
- 1.13 "Fraudulent practice" means a misrepresentation of facts in order to influence a procurement process or the execution of a contract to the detriment of any bidder, and includes collusive practice among bidders (prior to or after bid submission) designed to establish bid prices at artificial non-competitive levels and to deprive the bidder of the benefits of free and open competition.
- 1.14 "GCC" means the General Conditions of Contract.
- 1.15 "Goods" means all of the equipment, machinery, and/or other materials that the supplier is required to supply to the purchaser under the contract.
- 1.16 "Imported content" means that portion of the bidding price represented by the cost of components, parts or materials which have been or are still to be imported (whether by the supplier or his subcontractors) and which costs are inclusive of the costs abroad, plus freight and other direct importation costs such as landing costs, dock dues, import duty, sales duty or other similar tax or duty at the South African place of entry as well as transportation and handling charges to the factory in the Republic where the supplies covered by the bid will be manufactured.
- 1.17 "Local content" means that portion of the bidding price which is not included in the imported content provided that local manufacture does take place.
- 1.18 "Manufacture" means the production of products in a factory using labour, materials, components and machinery and includes other related value-adding activities.
- 1.19 "Order" means an official written order issued for the supply of goods or works or the rendering of a service.
- 1.20 "Project site," where applicable, means the place indicated in bidding documents.
- 1.21 "Purchaser" means the organization purchasing the goods.
- 1.22 "Republic" means the Republic of South Africa.
- 1.23 "SCC" means the Special Conditions of Contract.
- 1.24 "Services" means those functional services ancillary to the supply of the goods, such as transportation and any other incidental services, such as installation, commissioning, provision of technical assistance, training, catering, gardening, security, maintenance and other such

		obligations of the supplier covered under the contract.
	1.25	"Written" or "in writing" means handwritten in ink or any form of electronic or mechanical writing.
2. Application	2.1	These general conditions are applicable to all bids, contracts and orders including bids for functional and professional services, sales, hiring, letting and the granting or acquiring of rights, but excluding immovable property, unless otherwise indicated in the bidding documents.
	2.2	Where applicable, special conditions of contract are also laid down to cover specific supplies, services or works.
	2.3	Where such special conditions of contract are in conflict with these general conditions, the special conditions shall apply.
3. General	3.1	Unless otherwise indicated in the bidding documents, the purchaser shall not be liable for any expense incurred in the preparation and submission of a bid. Where applicable a non-refundable fee for documents may be charged.
	3.2	With certain exceptions, invitations to bid are only published in the Government Tender Bulletin. The Government Tender Bulletin may be obtained directly from the Government Printer, Private Bag X85, Pretoria 0001, or accessed electronically from www.treasury.gov.za
4. Standards	4.1	The goods supplied shall conform to the standards mentioned in the bidding documents and specifications.
5. Use of contract documents and information; inspection.	5.1	The supplier shall not, without the purchaser's prior written consent, disclose the contract, or any provision thereof, or any specification, plan, drawing, pattern, sample, or information furnished by or on behalf of the purchaser in connection therewith, to any person other than a person employed by the supplier in the performance of the contract. Disclosure to any such employed person shall be made in confidence and shall extend only so far as may be necessary for purposes of such performance.
	5.2	The supplier shall not, without the purchaser's prior written consent, make use of any document or information mentioned in GCC clause 5.1 except for purposes of performing the contract.
	5.3	Any document, other than the contract itself mentioned in GCC clause 5.1 shall remain the property of the purchaser and shall be returned (all copies) to the purchaser on completion of the supplier's performance under the contract if so required by the purchaser.
	5.4	The supplier shall permit the purchaser to inspect the supplier's records relating to the performance of the supplier and to have them audited by auditors appointed by the purchaser, if so required by the purchaser.
6. Patent rights	6.1	The supplier shall indemnify the purchaser against all third-party claims of infringement of patent, trademark, or industrial design rights arising from use of the goods or any part thereof by the purchaser.

	7. Performance security	7.1	Vithin thirty (30) days of receipt of the notifine successful bidder shall furnish to the pure curity of the amount specified in SCC.	
		7.2	The proceeds of the performance security urchaser as compensation for any loss result ailure to complete his obligations under the co	ting from the supplier's
		7.3	The performance security shall be denominated ontract, or in a freely convertible currency ac and shall be in one of the following forms:	
			<ul> <li>a bank guarantee or an irrevocable letreputable bank located in the purcha acceptable to the purchaser, in the bidding documents or another for purchaser; or</li> <li>a cashier's or certified cheque</li> </ul>	ser's country or abroad, form provided in the
		7.4	The performance security will be discharge eturned to the supplier not later than thirty ate of completion of the supplier's performan ontract, including any warranty obligat pecified in SCC.	(30) days following the nee obligations under the
1	8. Inspections, tests and analyses	8.1	Il pre-bidding testing will be for the account	of the bidder.
		8.2	It is a bid condition that supplies to be pro- endered should at any stage during produc completion be subject to inspection, the pro- contractor shall be open, at all reasonable ho epresentative of the Department or an organiz- ne Department.	tion or execution or on emises of the bidder or purs, for inspection by a
		8.3	there are no inspection requirements in ocuments and no mention is made in the ontract period it is decided that inspections urchaser shall itself make the necessary ayment arrangements with the testing authori	contract, but during the shall be carried out, the arrangements, including
		8.4	The inspections, tests and analyses referred now the supplies to be in accordance with the ne cost of the inspections, tests and analyses urchaser.	ne contract requirements,
		8.5	Where the supplies or services referred to in c omply with the contract requirements, irres upplies or services are accepted or not, the nese inspections, tests or analyses shall be def	pective of whether such cost in connection with
		8.6	upplies and services which are referred to in which do not comply with the contract requires	
		8.7	any contract supplies may on or after deliver	y be inspected, tested or

analyzed and may be rejected if found not to comply with the
requirements of the contract. Such rejected supplies shall be held at the
cost and risk of the supplier who shall, when called upon, remove them
immediately at his own cost and forthwith substitute them with
supplies which do comply with the requirements of the contract.
Failing such removal the rejected supplies shall be returned at the
suppliers cost and risk. Should the supplier fail to provide the
substitute supplies forthwith, the purchaser may, without giving the
supplier further opportunity to substitute the rejected supplies,
purchase such supplies as may be necessary at the expense of the
supplier.
**

- 8.8 The provisions of clauses 8.4 to 8.7 shall not prejudice the right of the purchaser to cancel the contract on account of a breach of the conditions thereof, or to act in terms of Clause 23 of GCC.
- 9. Packing
  9.1 The supplier shall provide such packing of the goods as is required to prevent their damage or deterioration during transit to their final destination, as indicated in the contract. The packing shall be sufficient to withstand, without limitation, rough handling during transit and exposure to extreme temperatures, salt and precipitation during transit, and open storage. Packing, case size and weights shall take into consideration, where appropriate, the remoteness of the goods' final destination and the absence of heavy handling facilities at all points in transit.
  - 9.2 The packing, marking, and documentation within and outside the packages shall comply strictly with such special requirements as shall be expressly provided for in the contract, including additional requirements, if any, specified in SCC, and in any subsequent instructions ordered by the purchaser.
- 10. Delivery<br/>and documents10.1Delivery of the goods shall be made by the supplier in accordance with<br/>the terms specified in the contract. The details of shipping and/or other<br/>documents to be furnished by the supplier are specified in SCC.
  - 10.2 Documents to be submitted by the supplier are specified in SCC.
- **11. Insurance** 11.1 The goods supplied under the contract shall be fully insured in a freely convertible currency against loss or damage incidental to manufacture or acquisition, transportation, storage and delivery in the manner specified in the SCC.
- **12. Transportation** 12.1 Should a price other than an all-inclusive delivered price be required, this shall be specified in the SCC.

# 13. Incidental<br/>services13.1The supplier may be required to provide any or all of the following<br/>services, including additional services, if any, specified in SCC:

- (a) performance or supervision of on-site assembly and/or commissioning of the supplied goods;
- (b) furnishing of tools required for assembly and/or maintenance of the supplied goods;
- (c) furnishing of a detailed operations and maintenance manual for each appropriate unit of the supplied goods;

14. Spare parts

- (d) performance or supervision or maintenance and/or repair of the supplied goods, for a period of time agreed by the parties, provided that this service shall not relieve the supplier of any warranty obligations under this contract; and
- (e) training of the purchaser's personnel, at the supplier's plant and/or on-site, in assembly, start-up, operation, maintenance, and/or repair of the supplied goods.
- 13.2 Prices charged by the supplier for incidental services, if not included in the contract price for the goods, shall be agreed upon in advance by the parties and shall not exceed the prevailing rates charged to other parties by the supplier for similar services.
- 14.1 As specified in SCC, the supplier may be required to provide any or all of the following materials, notifications, and information pertaining to spare parts manufactured or distributed by the supplier:
  - (a) such spare parts as the purchaser may elect to purchase from the supplier, provided that this election shall not relieve the supplier of any warranty obligations under the contract; and
  - (b) in the event of termination of production of the spare parts:
    - (i) Advance notification to the purchaser of the pending termination, in sufficient time to permit the purchaser to procure needed requirements; and
    - (ii)following such termination, furnishing at no cost to the purchaser, the blueprints, drawings, and specifications of the spare parts, if requested.
- 15. Warranty 15.1 The supplier warrants that the goods supplied under the contract are new, unused, of the most recent or current models, and that they incorporate all recent improvements in design and materials unless provided otherwise in the contract. The supplier further warrants that all goods supplied under this contract shall have no defect, arising from design, materials, or workmanship (except when the design and/or material is required by the purchaser's specifications) or from any act or omission of the supplier, that may develop under normal use of the supplied goods in the conditions prevailing in the country of final destination.
  - 15.2 This warranty shall remain valid for twelve (12) months after the goods, or any portion thereof as the case may be, have been delivered to and accepted at the final destination indicated in the contract, or for eighteen (18) months after the date of shipment from the port or place of loading in the source country, whichever period concludes earlier, unless specified otherwise in SCC.
  - 15.3 The purchaser shall promptly notify the supplier in writing of any claims arising under this warranty.
  - 15.4 Upon receipt of such notice, the supplier shall, within the period specified in SCC and with all reasonable speed, repair or replace the defective goods or parts thereof, without costs to the purchaser.
  - 15.5 If the supplier, having been notified, fails to remedy the defect(s) within the period specified in SCC, the purchaser may proceed to take

		such remedial action as may be necessary, at the supplier's risk and expense and without prejudice to any other rights which the purchaser may have against the supplier under the contract.
16. Payment	16.1	The method and conditions of payment to be made to the supplier under this contract shall be specified in SCC.
	16.2	The supplier shall furnish the purchaser with an invoice accompanied by a copy of the delivery note and upon fulfillment of other obligations stipulated in the contract.
	16.3	Payments shall be made promptly by the purchaser, but in no case later than thirty (30) days after submission of an invoice or claim by the supplier.
	16.4	Payment will be made in Rand unless otherwise stipulated in SCC.
17. Prices	17.1	Prices charged by the supplier for goods delivered and services performed under the contract shall not vary from the prices quoted by the supplier in his bid, with the exception of any price adjustments authorized in SCC or in the purchaser's request for bid validity extension, as the case may be.
18. Contract amendments	18.1	No variation in or modification of the terms of the contract shall be made except by written amendment signed by the parties concerned.
19. Assignment	19.1	The supplier shall not assign, in whole or in part, its obligations to perform under the contract, except with the purchaser's prior written consent.
20. Subcontracts	20.1	The supplier shall notify the purchaser in writing of all subcontracts awarded under this contracts if not already specified in the bid. Such notification, in the original bid or later, shall not relieve the supplier from any liability or obligation under the contract.
21. Delays in the supplier's performance	21.1	Delivery of the goods and performance of services shall be made by the supplier in accordance with the time schedule prescribed by the purchaser in the contract.
	21.2	If at any time during performance of the contract, the supplier or its subcontractor(s) should encounter conditions impeding timely delivery of the goods and performance of services, the supplier shall promptly notify the purchaser in writing of the fact of the delay, its likely duration and its cause(s). As soon as practicable after receipt of the supplier's notice, the purchaser shall evaluate the situation and may at his discretion extend the supplier's time for performance, with or without the imposition of penalties, in which case the extension shall be ratified by the parties by amendment of contract.
	21.3	No provision in a contract shall be deemed to prohibit the obtaining of supplies or services from a national department, provincial department, or a local authority.
	21.4	The right is reserved to procure outside of the contract small quantities or to have minor essential services executed if an emergency arises, the

supplier's point of supply is not situated at or near the place where the supplies are required, or the supplier's services are not readily available.

- 21.5 Except as provided under GCC Clause 25, a delay by the supplier in the performance of its delivery obligations shall render the supplier liable to the imposition of penalties, pursuant to GCC Clause 22, unless an extension of time is agreed upon pursuant to GCC Clause 21.2 without the application of penalties.
- 21.6 Upon any delay beyond the delivery period in the case of a supplies contract, the purchaser shall, without canceling the contract, be entitled to purchase supplies of a similar quality and up to the same quantity in substitution of the goods not supplied in conformity with the contract and to return any goods delivered later at the supplier's expense and risk, or to cancel the contract and buy such goods as may be required to complete the contract and without prejudice to his other rights, be entitled to claim damages from the supplier.
- 22. Penalties 22.1 Subject to GCC Clause 25, if the supplier fails to deliver any or all of the goods or to perform the services within the period(s) specified in the contract, the purchaser shall, without prejudice to its other remedies under the contract, deduct from the contract price, as a penalty, a sum calculated on the delivered price of the delayed goods or unperformed services using the current prime interest rate calculated for each day of the delay until actual delivery or performance. The purchaser may also consider termination of the contract pursuant to GCC Clause 23.
  - 23.1 The purchaser, without prejudice to any other remedy for breach of contract, by written notice of default sent to the supplier, may terminate this contract in whole or in part:
    - (a) if the supplier fails to deliver any or all of the goods within the period(s) specified in the contract, or within any extension thereof granted by the purchaser pursuant to GCC Clause 21.2;
    - (b) if the Supplier fails to perform any other obligation(s) under the contract; or
    - (c) if the supplier, in the judgment of the purchaser, has engaged in corrupt or fraudulent practices in competing for or in executing the contract.
    - 23.2 In the event the purchaser terminates the contract in whole or in part, the purchaser may procure, upon such terms and in such manner as it deems appropriate, goods, works or services similar to those undelivered, and the supplier shall be liable to the purchaser for any excess costs for such similar goods, works or services. However, the supplier shall continue performance of the contract to the extent not terminated.
    - 23.3 Where the purchaser terminates the contract in whole or in part, the purchaser may decide to impose a restriction penalty on the supplier by prohibiting such supplier from doing business with the public sector for a period not exceeding 10 years.
    - 23.4 If a purchaser intends imposing a restriction on a supplier or any

11

23. Termination for default

person associated with the supplier, the supplier will be allowed a time period of not more than fourteen (14) days to provide reasons why the envisaged restriction should not be imposed. Should the supplier fail to respond within the stipulated fourteen (14) days the purchaser may regard the intended penalty as not objected against and may impose it on the supplier.

- 23.5 Any restriction imposed on any person by the Accounting Officer / Authority will, at the discretion of the Accounting Officer / Authority, also be applicable to any other enterprise or any partner, manager, director or other person who wholly or partly exercises or exercised or may exercise control over the enterprise of the first-mentioned person, and with which enterprise or person the first-mentioned person, is or was in the opinion of the Accounting Officer / Authority actively associated.
- 23.6 If a restriction is imposed, the purchaser must, within five (5) working days of such imposition, furnish the National Treasury, with the following information:
  - (i) the name and address of the supplier and / or person restricted by the purchaser;
  - (ii) the date of commencement of the restriction
  - (iii) the period of restriction; and
  - (iv) the reasons for the restriction.

These details will be loaded in the National Treasury's central database of suppliers or persons prohibited from doing business with the public sector.

- 23.7 If a court of law convicts a person of an offence as contemplated in sections 12 or 13 of the Prevention and Combating of Corrupt Activities Act, No. 12 of 2004, the court may also rule that such person's name be endorsed on the Register for Tender Defaulters. When a person's name has been endorsed on the Register, the person will be prohibited from doing business with the public sector for a period not less than five years and not more than 10 years. The National Treasury is empowered to determine the period of restriction and each case will be dealt with on its own merits. According to section 32 of the Act the Register must be open to the public. The Register can be perused on the National Treasury website.
- 24. Anti-dumping 24.1 When, after the date of bid, provisional payments are required, or antiand countervailing dumping or countervailing duties are imposed, or the amount of a duties and rights provisional payment or anti-dumping or countervailing right is increased in respect of any dumped or subsidized import, the State is not liable for any amount so required or imposed, or for the amount of any such increase. When, after the said date, such a provisional payment is no longer required or any such anti-dumping or countervailing right is abolished, or where the amount of such provisional payment or any such right is reduced, any such favourable difference shall on demand be paid forthwith by the contractor to the State or the State may deduct such amounts from moneys (if any) which may otherwise be due to the contractor in regard to supplies or services which he delivered or rendered, or is to deliver or render in terms of the contract or any other contract or any other amount which

may be due to him

25. Force Majeure	25.1	Notwithstanding the provisions of GCC Clauses 22 and 23, the supplier shall not be liable for forfeiture of its performance security damages, or termination for default if and to the extent that his delay in performance or other failure to perform his obligations under the contract is the result of an event of force majeure.				
	25.2	If a force majeure situation arises, the supplier shall promptly notify the purchaser in writing of such condition and the cause thereof. Unless otherwise directed by the purchaser in writing, the supplier shall continue to perform its obligations under the contract as far as is reasonably practical, and shall seek all reasonable alternative means for performance not prevented by the force majeure event.				
<b>26. Termination</b> for insolvency	26.1	The purchaser may at any time terminate the contract by giving written notice to the supplier if the supplier becomes bankrupt or otherwise insolvent. In this event, termination will be without compensation to the supplier, provided that such termination will not prejudice or affect any right of action or remedy which has accrued or will accrue thereafter to the purchaser.				
27. Settlement of Disputes	27.1	If any dispute or difference of any kind whatsoever arises between the purchaser and the supplier in connection with or arising out of the contract, the parties shall make every effort to resolve amicably such dispute or difference by mutual consultation.				
	27.2	If, after thirty (30) days, the parties have failed to resolve their dispute or difference by such mutual consultation, then either the purchaser or the supplier may give notice to the other party of his intention to commence with mediation. No mediation in respect of this matter may be commenced unless such notice is given to the other party.				
	27.3	Should it not be possible to settle a dispute by means of mediation, it may be settled in a South African court of law.				
	27.4	Mediation proceedings shall be conducted in accordance with the rules of procedure specified in the SCC.				
	27.5	Notwithstanding any reference to mediation and/or court proceedings herein,				
		<ul><li>(a) the parties shall continue to perform their respective obligations under the contract unless they otherwise agree; and</li><li>(b) the purchaser shall pay the supplier any monies due the supplier.</li></ul>				
28. Limitation of liability	28.1	<ul> <li>Except in cases of criminal negligence or willful misconduct, and in the case of infringement pursuant to Clause 6;</li> <li>(a) the supplier shall not be liable to the purchaser, whether in contract, tort, or otherwise, for any indirect or consequential loss or damage, loss of use, loss of production, or loss of profits or interest costs, provided that this exclusion shall not apply to any obligation of the supplier to pay penalties and/or damages to the purchaser; and</li> </ul>				

		(b) the aggregate liability of the supplier to the purchaser, whether under the contract, in tort or otherwise, shall not exceed the total contract price, provided that this limitation shall not apply to the cost of repairing or replacing defective equipment.
29. Governing language	29.1	The contract shall be written in English. All correspondence and other documents pertaining to the contract that is exchanged by the parties shall also be written in English.
30. Applicable law	30.1	The contract shall be interpreted in accordance with South African laws, unless otherwise specified in SCC.
31. Notices	31.1	Every written acceptance of a bid shall be posted to the supplier concerned by registered or certified mail and any other notice to him shall be posted by ordinary mail to the address furnished in his bid or to the address notified later by him in writing and such posting shall be deemed to be proper service of such notice
	31.2	The time mentioned in the contract documents for performing any act after such aforesaid notice has been given, shall be reckoned from the date of posting of such notice.
<b>32.</b> Taxes and duties	32.1	A foreign supplier shall be entirely responsible for all taxes, stamp duties, license fees, and other such levies imposed outside the purchaser's country.
	32.2	A local supplier shall be entirely responsible for all taxes, duties, license fees, etc., incurred until delivery of the contracted goods to the purchaser.
	32.3	No contract shall be concluded with any bidder whose tax matters are not in order. Prior to the award of a bid the Department must be in possession of a tax clearance certificate, submitted by the bidder. This certificate must be an original issued by the South African Revenue Services.
33. National Industrial Participation (NIP) Programme	33.1	The NIP Programme administered by the Department of Trade and Industry shall be applicable to all contracts that are subject to the NIP obligation.
34 Prohibition of Restrictive practices	Ir	n terms of section 4 (1) (b) (iii) of the Competition Act No. 89 of 1998, as amended, an agreement between, or concerted practice by, firms, or a decision by an association of firms, is prohibited if it is between parties in a horizontal relationship and if a bidder (s) is / are or a contractor(s) was / were involved in collusive bidding (or bid rigging).
	34.2	If a bidder(s) or contractor(s), based on reasonable grounds or evidence obtained by the purchaser, has / have engaged in the restrictive practice referred to above, the purchaser may refer the matter to the Competition Commission for investigation and possible imposition of administrative penalties as contemplated in the Competition Act No. 89 of 1998.
	34.3	If a bidder(s) or contractor(s), has / have been found guilty by the Competition Commission of the restrictive practice referred to above, the purchaser may, in addition and without prejudice to any other remedy provided for, invalidate the bid(s) for such item(s) offered, and / or

terminate the contract in whole or part, and / or restrict the bidder(s) or contractor(s) from conducting business with the public sector for a period not exceeding ten (10) years and / or claim damages from the bidder(s) or contractor(s) concerned.

Js General Conditions of Contract (revised July 2010)



# SPECIAL REQUIREMENTS AND CONDITIONS OF CONTRACT

HP02-2021AI

SUPPLY AND DELIVERY OF ANTI-INFECTIVE MEDICINES (ANTIBIOTICS, ANTIFUNGAL, ANTIPROTOZOAL AND ANTIVIRAL AGENTS) TO THE DEPARTMENT OF HEALTH FOR THE PERIOD 01 OCTOBER 2021 TO 30 SEPTEMBER 2023

BID VALIDITY PERIOD: 120 DAYS

# CLOSING DATE AND TIME OF BID:

30 NOVEMBER AT 11H00

NO BRIEFING SESSION WILL BE HELD.



## TABLE OF CONTENTS

1. LEGISLATIVE AND REGULATORY FRAMEWORK	8
10. LATE BIDS	
11. COUNTER CONDITIONS	20
12. FRONTING	20
13. SUPPLIER DUE DILIGENCE	20
14. COMMUNICATION	20
15. CONTACT DETAILS	
16. CONTRACT PERIOD	
17. PARTICIPATING AUTORITIES AND OTHER HEALTH ESTABLIHSMENT	22
18. REGISTRATION ON DATABASES OF PARTICIPATING AUTHORITIES	
19. POST AWARD PARTICIPATION	
2. BID INFORMATION SESSION	
2. BID INFORMATION SESSION	
21 NEGOTIATIONS	
22. NON-COMMITMENT	
23. PRICE REVIEW	
23.1 ELIGIBILITY RELATING TO RATE OF EXCHANGE ADJUSTMENTS	
23.2 PRICE ADJUSTMENTS RELATING TO FOREIGN EXCHANGE RISK	
23.3 APPLICATION FOR CONTRACTUAL PRICE ADJUSTMENTS	
23.4 ROUTINE PRICE ADJUSTMENTS	
23.5 EXCEPTIONAL PRICE ADJUSTMENTS	
23.6 PRICE ADJUSTMENTS BASED ON A SYSTEMATIC REVIEW	
24. QUALITY	
25. DELIVERY AND QUANTITIES	31
26. SUPPLIER PERFORMANCE MANAGEMENT	32
27. PACKAGING, LABELLING AND BARCODES	36
28 SHELF LIFE	38
29. CEDING, MERGERS, TAKE OVERS AND CHANGES IN SUPPLIER DETAILS	38
3. EVALUATION CRITERIA	
3.1 PHASE II: MANDATORY REQUIREMENTS	
3.1.1 LEGISLATIVE REQUIREMENTS TO THIS BID	
3.1.2 RESPONSIVE BIDS	
3.1.3 BID RESPONSE DOCUMENT	
3.1.4 AUTHORISATION DECLARATION	
3.1.5 TAX COMPLIANCE STATUS	
30. THIRD PARTIES	
4. PHASE III: PRODUCT TECHNICAL COMPLIANCE	
4. FINASE III. FRODUCT TECHNICKE COMPETANCE	
5. PHASE IV: PREFERENCE POINT SYSTEM	
6. PREFERENCE FOR LOCALLY PRODUCED PRODUCTS	
7. VALUE ADDED TAX	
8. SUBMISSION OF BIDS	-
9. COMPLETION OF DOCUMENTS AND BID SUBMISSION	
ABBREVIATIONS	
BID DOCUMENT CHECK LIST	
SECTION A	-
SECTION B	
SECTION C	32



## **ABBREVIATIONS**

API	: Active Pharmaceutical Ingredient
BAC	: Bid Adjudication Committee
B-BBEE	: Broad-Based Black Economic Empowerment
CPA	: Contract Price Adjustment
CSD	: Central Supplier Database
EAN	: European Article Numbering
EME	: Exempted Micro Enterprise
GMP	: Good Manufacturing Practice
MCC	: Medicines Control Council
MHPL	: Master Health Products List
MPC	: Master Procurement Catalogue
NDoH	: National Department of Health
PPPFA	: Preferential Procurement Policy Framework Act
QSE	: Qualifying Small Enterprise
RoE	: Rate of Exchange
SAHPRA	: South African Health Products Regulatory Authority
SARS	: South African Revenue Service
SBD	: Standard Bidding Document
VAT	: Value- Added Tax



## **BID DOCUMENT CHECK LIST**

All bid documents listed below must be sorted, filed and submitted in the **exact** compilation sequenceas indicated below and the annexure attached.

Submission of bid documents is compulsory, unless it's not applicable and indicated as such in the "N/A" column.

#### All bid documents must be signed.

Bidders not complying to any of the requirements may deemed to be non-responsive and will not be considered for evaluation

Compilation Sequence	Admin Code	Document Name	N/A	Yes	No	Remark
1	CL	Covering Letter				
2	BSRA	Bid Signature. Resolution/Authority to sign bid				
3	BFI	Bid/File Index				
4	PBD4.1	PBD 4.1: Contact Details of Bidder				
5	SBD5.1	SBD 1: Invitation to bid				
6	TCP	Tax Clearance Pin Issued				
7	CSD	CSD Registration report - A certified copy of latest and complete report. Note: CSD summary report will not be accepted.				
8	SBD4	SBD 4: Declaration of interest				
9	PBD9	PBD9: Directors: Categorisation by race, gender and disability				
10	SBD5	SBD5: The National Industrial Participation Programme				
11	SBD6	SBD 6(1): Preference Points Claimed (B- BBEE)				
12	BBBEE	Valid B-BBEE certificate <u>(certified copy of the</u> <u>original</u> ) or Sworn Affidavit to claim preference points				



Compilation Sequence	Admin Code	Document Name	N/A	Yes	No	Remark
13	SBD8	SBD 8: Declaration of Past SCM Practices				
14	SBD9	SBD 9: Certificate of Independent Bid Determination				
15	PBD1	PBD1: Authorisation Declaration Note: Non-compliance to submission of a valid authorisation declaration, where applicable, may invalidate the bid.				
16	PBD1.1	PBD 1.1: List of products offered sourced from third party				
17	PBD1.2	PBD 1.2: Unconditional written undertaking from the third party.				
18	PBD5	PBD5: Good Manufacturing Practice (GMP). Declaration of compliance.				
19	PBD8	PBD 8: Special Requirements and Conditions of Contact. Declaration of compliance.				
20	CIPC	CIPC/CIPRO or proof of ownership/shareholding. Certified copies of registration certificates				
21	NC	Proof of company cedings, mergers and name changes				
22	LICMI	Licence to manufacture or import (in the name of the bidder), <u>including all annexures.</u> <u>Certified copies required.</u>				
23	LICM	Licence to manufacture medicines,including all annexures <u>for local manufacturing sites</u> as listed on the MRC of the bidder (applicant). Certified copies required.				
24	MRC	Medicine Registration Certificates (MRC) with all the associated conditions of registration - Certified copies <u>Note: All MRC's must be marked by the</u> <u>bidder with the relevant item number and</u> <u>be sorted and filed in numerical order</u> .				



Compilation Sequence	Admin Code	Document Name	N/A	Yes	No	Remark			
25	PI	Original Package Insert (PI) or document detailing professional information approved by the Medicines Control Council (MCC) or the South African Health Products Regulatory Authority (SAHPRA) for each product offered. Note: All PI's must be marked with the relevant item number and be sorted and filed/submitted in numerical order.							
26	PS	Proof of sample submission							
27	BL	Bidder`s item list (List of products offered)							
28	PRICE	<b>Signed</b> Excel Bid Response Pricing Schedule If the Excel Bid response Pricing Schedule is not signed in the space provided, the bid will not be considered for evaluation.							
All bid	All bid documents listed above must be sorted, filed and submitted in the exact order as indicated above								
Submission	Submission of supporting bid documents is compulsory, unless it's not applicable and indicated as such in the "N/A" column								

The bid document check list is available as Annexure A in an excel spreadsheet format and should be completed by all bidders and be submitted in hard copy and as part of the electronic copies of "<u>Set 3: Electronic version of bid documents"</u>



## **SECTION A**

## 1. LEGISLATIVE AND REGULATORY FRAMEWORK

This bid and all contracts emanating there from will be subject to the Medicines and Related Substances Act, (Act 101 of 1965), Pharmacy Act, (Act 53 of 1974); Patents Act, 1978 (Act 57 of 1978); Trade Marks Act, 1993 (Act 194 of 1993); General Conditions of Contract issued in accordance with Treasury Regulation 16A published in terms of the Public Finance Management Act, 1999 (Act 1 of 1999). The Special Conditions of Contract (SCC) are supplementary to General Conditions of Contract (GCC). Where, however, the Special Conditions of Contract are in conflict with the General Conditions of Contract, the Special Conditions of Contract prevail.

## 2. BID INFORMATION SESSION

As the National Department of Health complies with the regulations made under the Disaster Management Act, 2002, published in the Gazette 18 March 2020 no briefing session or public bid opening will be held.

It is strongly **recommended** that all prospective bidders submit all enquiries to <u>tenders@health.gov.za</u> on time to allow the response to reach the bidders before the tender closes.

## 3. EVALUATION CRITERIA

The evaluation process will be conducted in phases as follows:

Phase I	Phase II	Phase III	Phase IV	
Mandatory and other bid requirements	Product technical compliance	Price and B-BBEE	Recommendation and Award	
Compliance with mandatory and other bid requirements	Compliance with technical specifications Test reports received from sample evaluation	Bids evaluated in terms of the 90/10 preference system	Recommendation and award	



## 3.1 PHASE I: MANDATORY REQUIREMENTS

Bidders must submit all required documents indicated above with the bid documents at the closing date and time of the bid. During this evaluation phase, bidder's responses will be evaluated based on the documents submitted under mandatory requirements. This phase is not scored and bidders who fail to comply with all mandatory requirements will be disqualified.

## 3.1.1 LEGISLATIVE REQUIREMENTS TO THIS BID

Items offered must be registered in terms of section 15 of the Medicines and Related Substances Act, 1965 (Act 101 of 1965), and must comply with the conditions of registration for the duration of the contract.

A certified copy of the original Medicine Registration Certificate, issued in terms of section 15(3) (a) of the Medicines and Related Substances Act, 1965 (Act 101 of 1965), must be included with the bid for all items offered.

The bidder must be indicated as the applicant on the Medicines Registration Certificate.

The bidder offering a product must be the holder of a licence to manufacture or import medicines issued in terms of section 22C (1) (b) of the Medicines and Related Substances Act, 1965 (Act 101 of 1965) including all annexures. A <u>certified copy</u> of the original licence must be submitted by the bidder offering the product.

The bidder offering a product must submit a <u>certified copy</u> of the original licence to manufacture medicines, including all annexures for local manufacturing sites listed on the MRC of the bidder who must also be the applicant.

Bidders must comply with the requirements of the Patents Act, 1978 (Act 57 of 1978) and the Trade Marks Act, 1993 (Act 194 of 1993). Where applicable, an explanation for any non-compliance must be provided. In the case where a product is manufactured under a voluntary license issued by the patent holder of such a product, a letter authorising the marketing of the product, provided to the bidder by the patent holder must be submitted with the bid.



## 3.1.2 RESPONSIVE BIDS

Bidders are required to submit responsive bids by completing all the prices in the Excel Bid Response. **All prices must be submitted with 2 (two) decimals**. Document and response fields in the fillible PDF bid document. In this regard, bidder's attention is drawn to the document "Definition of fields in the Bid Response Document" explaining the different fields in the bid document.

## 3.1.3 BID DOCUMENTS

Bidders are required to submit responsive bids by completing all the prices, mandatory response fields and item questionnaires.

The excel bid response documents i.e. pricing schedule and Directors: Categorisation of race, gender and disability provided forms an integral part of the bid document and bidders must ensure that it is completed without changing the structure thereof.All pages must be signed.

The prices quoted must be furnished as all inclusive (incl. VAT) on the basis of supply and delivery. **All prices <u>must</u> be submitted withtwo (2) decimals**.

The bid price offered for a product is deemed to be for the pack size as advertised in the item specification and the unit specified.

Prices submitted must not exceed the ex-manufacturer component of the Single Exit Price inclusive of VAT.

## 3.1.4 AUTHORISATION DECLARATION

Only the holder of a Medicines Registration Certificate issued in terms of the Medicines and Related Substances Act, 1965 (Act 101 of 1965), may submit a bid.

In the event that the Manufacturer, Packer or other entity, as listed on the certificate of registration are external third parties, the bidder must ensure that all legal, financial and supply arrangements have been mutually agreed upon between the bidder and these third parties.



Where a third party is involved in any capacity, the bidder must submit a duly completed and signed Authorisation Declaration (PBD1) for each such third party.

The National Department of Health reserves the right to verify any information supplied by the bidder in the Authorisation Declaration and, should the information be found to be false or incorrect, the National Department of Health will exercise any of the remedies available to it in the bid documents.

Failure to submit a duly completed and signed Authorisation Declaration, with the required annexure(s), in accordance with the above provisions, will invalidate the bid for such goods or services offered.

No agreement between the bidder and any third party will be binding on the National Department of Health.

## 3.1.5 TAX COMPLIANCE STATUS

The Central Supplier Database and the tax compliance status PIN are the approved methods of verifying the tax compliance status of a bidder. The South African Revenue Service does not issue Tax Clearance Certificates anymore but has introduced an online provision via eFiling, for bidders to print their own Tax Clearance Certificates which they can submit with their bids or price quotations.

It is a condition of this bid that the tax matters of the bidder be in order at any point in time, or that satisfactory arrangements have been made with SARS to meet the bidder's tax obligations. It is a requirement that bidders grant a written confirmation when submitting this bid that SARS may, on an on-going basis during the tenure of the contract, disclose the bidder's tax compliance status and, by submitting this bid, such confirmation is deemed to have been granted.

Bidders are required to be registered on the **Government's Central Supplier Database** and to include in their bid **their Master Registration Number (Supplier Number)** in order to enable the institution to verify the supplier's tax status on the Central Supplier Database;.

Foreign suppliers with neither South African tax obligations nor history of doing business in South Africa must complete the questionnaire on the SBD1. Where a recommendation for award of a bid has



been made to a foreign bidder, the NDOH will submit the bidder's completed SBD1 to the South African RevenueService to emailaddress: GovernmentInstitute@sars.gov.za. The South African Revenue Service will issue a confirmation of tax obligations letter to the NDOH, confirming whether or not the foreign entity has tax obligations in South Africa

Should the recommended bidder fail to provide written proof of their tax compliance status, the NDOH wullreject the bid submitted by the bidder.

The National Department of Health shall verify the bidder's tax compliance status through the CSD. Where consortia/joint ventures/sub-contractors are involved, each party must be registered on the Central Supplier Database and their tax compliance status will be verified through the Central Supplier Database. Bidders remain responsible to update their CSD information in line with the bid documents submitted for this bid.

## 4. PHASE II: PRODUCT TECHNICAL COMPLIANCE

## 4.1 SAMPLES TO BE SUBMITTED TO HEALTH ESTABLISHMENTS

All bidders are required to submit samples, including bidders who are currently supplying the National Department of Health with products to confirm the following:

- Compliance with specifications as set out in the bid document/item specification.
- Compliance of the product with the requirements of the Medicines and Related Substances Act, 1965 (Act 101 of 1965).

Failure to submit samples at both health establishments listed below will invalidate the bid for such items offered. Samples are required to be submitted to each (both) of the addresses indicated below prior to closing date and time of bid:



Mr DumisaniMalele	Mr Nisaar Mia	
Depot Manager	Pharmaceutical Policy Specialist	
Tel: 011 628 9131	Tel: 021 483 5800	
Gauteng: Medical Supplies Depot	Western Cape: Department of Health	
Store 3	4th Floor, Cape Medical Depot	
35 Plunkett Avenue	16 Chiappini Street	
Hurst Hill	Cape Town	
2092	8001	

- No samples must be sent to the National Department of Health.
- Samples must be marked with the bid number, the item number as well as the bidder's name and address.
- Bidders must submit at least one original pack of each offer for evaluation.
- It is the responsibility of the bidder to ensure that samples have been received at the addresses provided above.
- All samples for awarded items will be retained for the period of the contract.
- All samples must be a true representation of the product which will be supplied.
- All samples submitted must include the package insert or document detailing professional information approved by the MCC or SAHPRA.
- Proof of sample submission, including a signed copy of the item list as received by the sample evaluation site, must be submitted with the bid documents at the closing date and time of the bid.



## 4.2 COMPLIANCE WITH SPECIFICATIONS

Items must comply with the specification as detailed in the bid document.

## 5. PHASE IV: PREFERENCE POINT SYSTEM

## 5.1 A MAXIMUM OF 80 OR 90 POINTS IS ALLOCATED FOR PRICE ON THE FOLLOWING BASIS:

80/20 or 90/10  $Ps = 80\left(1 - \frac{Pt - P\min}{P\min}\right) or Ps = 90\left(1 - \frac{Pt - P\min}{P\min}\right)$ Where Ps = Points scored for price of bid under consideration Pt = Price of bid under consideration Pmin = Price of lowest acceptable bid

## 5.2 POINTS AWARDED FOR B-BBEE STATUS LEVEL OF CONTRIBUTOR

In terms of Regulation 6(2) and 7(2) of the Preferential Procurement Regulations, preference points must be awarded to a bidder for attaining the B-BBEE status level of contribution in accordance with the table below:

B-BBEE Status Level of Contributor	Number of points (90/10 system)	Number of points (80/20 system)
1	10	20
2	9	18
3	6	14
4	5	12
5	4	8
6	3	6
7	2	4
8	1	2
Non-compliant contributor	0	0

For this tender, the 90/10 preference point system will be applied.

- Bidders are required to complete the preference claim form (SBD 6.1), and submit a valid certified copy of the original B-BBEE status level verification certificate, at the closing date and time of the bid in order to claim the B-BBEE status level point.
- The points scored by a bidder in respect of the level of B-BBEE contribution will be added to the points scored for price.
- Only bidders who have completed and signed the declaration part of the preference claim form and who have submitted a certified copy of an original B-BBEE status level certificate issued by a registered auditor, accounting officer (as contemplated in section 60(4) of the Close Corporation Act, 1984 (Act No. 69 of 1984)) or an accredited verification agency will be considered for preference points.
- Exempted Micro Enterprises (EME's) and Qualifying Small Enterprices (QSE's) must submit a Sworn Affidavit as prescribed by the B-BBEE Commssion, Practice Guide 01 of 2019.
- Sworn Affidavits submitted by EME's and QSE will strictly be evaluated according the the guidelines as prescribed by the B-BBEE Commission.
- If the bidder fails to comply with the paragraphs above, the bidder will be deemed not to have claimed
  preference points for B-BBEE status level of contribution and will therefore be allocated a zero (0). The National
  Department of Health may, before a bid is adjudicated or at any time, require a bidder to substantiate claims it
  has made with regard to preference claimed. The points scored will be rounded off to the nearest two (2)
  decimals.In the event that two (2) or more bids have scored equal total points, the contract will be awarded to
  the bidder scoring the highest number of preference points for B-BBEE.
- A contract may, on reasonable and justifiable grounds, be awarded to a bid that did not score the highest number of points.

## 6. PREFERENCE FOR LOCALLY PRODUCED PRODUCTS

The National Department of Health reserves the right to consider locally produced products offered. Bidders are required to indicate on the Excel Bid Response Document where the products are manufactured. In order to provide preference to locally produced products, the definition of a locally produced product will be limited to product formulation and conversion processes that use materials and components to manufacture medicines (including importation of raw material of active pharmaceutical ingredients (API) and of excipients for production of finished products) in the Republic of South Africa.



Where the National Department of Health gives preference to locally produced products, the quantities for these items will be allocated and awarded proportionately to locally produced products, provided this does not **negatively impact upon security of supply and affordability**.

Bids for products that qualify for this preference must comply with all of the following criteria:

- The South African Health Product Authority (SAHPRA) certificate of registration for a product lists the primary site of production as one that is located in the Republic of South Africa;
- The bidder offering a product must be the holder of a licence to manufacture or import medicines issued in terms of section 22C (1) (b) of the Medicines and Related Substances Act, 1965 (Act 101 of 1965) including all annexures. A <u>certified copy</u> of the original licence must be submitted by the bidder offering the product.
- The bidder offering a product must submit a <u>certified copy</u> of the originallicence to manufacture medicines, including all annexures for local manufacturing sites listed on the MRC of the bidder who must also be the applicant.
- The reference price as published by National Department of Health has not been exceeded (if applicable);
- The site/s of manufacture and/or packaging for the product offered is located in South Africa;
- Demonstrated capacity to service the required volumes as evaluated in terms of the data provided in the Excel Bid Response Document;
- Previous supplier performance;
- Compliance to all other aspects contained in these Special Conditions of Contract

## 7. VALUE ADDED TAX

All bid prices must be inclusive of 15% Value-Added Tax. Failure to comply with this condition will invalidate the bid.

## 8. SUBMISSION OF BIDS

All bid documents listed below must be sorted, filed and submitted in the exact compilation sequence as indicated below and the annexure attached.

Submission of bid documents is mandatory, unless it's not applicable and indicated as such in the "N/A" column in the Bid Document Check List.

All bid documents must be signed.



Bidders not complying to any of the requirements may be deemed to be non-responsive and will not be considered for evaluation.

- Covering Letter i.e. limited stock availability of any item offered, non-compliance;
- Status relating to TAX, B-BBEE, License to Manufacture, Certificates etc. Bid Signature;
- Resolution/Authority to sign bid;
- Bid/File Index;
- PBD 4.1: Contact Details of Bidder;
- SBD 1: Invitation to bid;
- Tax Clearance Pin Issued;
- CSD Registration report A certified copy of latest and complete report. Note: CSD summary report will not be accepted;
- SBD 4: Declaration of interest;
- PBD9: Directors: Categorisation by race, gender and disability;
- SBD5: The National Industrial Participation Programme;
- SBD 6(1): Preference Points Claimed (B-BBEE);
- Valid B-BBEE certificate (certified copy) or Sworn Affidavit to claim preference points;
- SBD 8: Declaration of Past SCM Practices;
- SBD 9: Certificate of Independent Bid Determination;
- PBD1: Authorisation Declaration Note: Non-compliance to submission of a valid authorisation declaration, where applicable, may invalidate the bid;
- PBD 1.1: List of products offered sourced from third party;
- PBD 1.2: Unconditional written undertaking from the third party;
- PBD5: Good Manufacturing Practice (GMP). Declaration of compliance;
- PBD 8: Special Requirements and Conditions of Contact. Declaration of compliance;
- CIPC/CIPRO or proof of ownership/shareholding. Certified copies of registration certificates;
- Proof of company cedings, mergers and name changes;
- Certified copy of Licence to manufacture or import (in the name of the bidder), including all annexures;
- Certified copy of Licence to manufacture medicines, including all annexures for local manufacturing sites as listed on the MRC of the bidder (applicant);



- Certified copies of Medicine Registration Certificates (MRC) with all the associated conditions of registration (Annexure). Note: All MRC's must be marked by the bidder with the relevant item number and be sorted and filed in numerical order;
- Original Package Insert (PI) or document detailing professional information approved by the Medicines Control Council (MCC) or the South African Health Products Regulatory Authority (SAHPRA) for each product offered. Note: All PI's must be marked with the relevant item number and be sorted and filed/submitted in numerical
- order;
- Proof of sample submission;
- Bidder's item list (List of products offered); and
- Signed Excel Bid Response Pricing Schedule (All prices must be submitted in 2 (two) decimals). If the Excel Bid response Pricing Schedule is not signed in the space provided, the bid will not be considered for evaluation

## 9. COMPLETION OF DOCUMENTS AND BID SUBMISSION

Bidders are required to submit three sets of bid documents according to the instructions below. All three sets must be submitted not later than the closing date and time. Set 2 and Set 3 must be included on a CD with Set 1 and submitted in a sealed package. The full name and address of the bidder, including the return address, the bid number and the closing date must be clearly indicated on the package. All fields must be completed. Where information requested is not relevant this should be indicated with N/A.

## Set 1: Hard copy legally binding bid documents

Bidders must complete all SBD, PBD and Bid Response forms in black ink, typed. Where no electronic entry field is provided bidders must complete the forms in black ink, handwritten in capital letters. The signed hard copy of the bid document will serve as the legal bid document.

Bidders must submit their complete bid in hard copy format (paper document). The Chief Executive Officer, Chief Financial Officer, or authorised designee of the entity submitting the bid must sign the official signature pages. All pages in the complete bid document must be initialed by same with black ink. The use of correction fluid is not acceptable. Any change/s must be clearly indicated and initialed.

As the National Department of Health complies with the regulations made under the Disaster Management Act, 2002, published in the Gazette 18 March 2020 no briefing session or public bid opening will be held. However, Bidders must still ensure that bids are delivered on time to the correct address and deposited in the Tender Box. Late bids will not be accepted for consideration

Bidders must refrain from using binding methods like coil, comb, wire velobind, screw binding etc. It is requested that bidders pre-punch two holes on the left hand side of bid documents suitable for filing in a two hole lever arch file. Bid documents should be tied in parcels using string or rope that can be easily untied for filing purposes.

## Set 2: PDF of Hard Copy, signed legal documents. (i.e. pdf of Set 1)

Bidders must submit a PDF version of the entire signed hardcopy bid, including all certificates and documents requested.

## Set 3: Electronic version of bid documents

Bidders must submit the electronic versions (editable pdf) of all SBD and PBD documents, Bid Response Document and other relevant spreadsheets in Excel (not pdf).

All three sets of information must be submitted in order for the bid to be evaluated.

Bidders must ensure that the **price quoted** for a product (line item) on the Bid Response Document is for the unit pack as specified. No conversion factors will be applied.

## 10. LATE BIDS

Bids received after the closing date and time, at the address indicated in the bid documents, will not be accepted for consideration and, where practical, be returned unopened to the bidder.



#### **11. COUNTER CONDITIONS**

Bidders' attention is drawn to the fact that amendments to any of the bid conditions or setting of counter conditions by bidders may result in the invalidation of such bids.

#### 12. FRONTING

The National Department of Health supports the spirit of broad based black economic empowerment and recognises that real empowerment can only be achieved through individuals and businesses conducting themselves in accordance with the Constitution and in an honest, fair, equitable, transparent and legally compliant manner. Against this background, the National Department of Health condemns any form of fronting.

The National Department of Health, in ensuring that bidders conduct themselves in an honest manner will, as part of the bid evaluation processes, conduct or initiate the necessary enquiries/investigations to determine the accuracy of the representation made in bid documents. Should any of the fronting indicators as contained in the Guidelines on Complex Structures and Transactions and Fronting, issued by the Department of Trade and Industry, be established during such enquiry/investigation, the onus will be on the bidder/contractor to prove that fronting does not exist. Failure to do so within a period of 14 days from date of notification, may invalidate the bid/ contract and may also result in the restriction of the bidder/contractor to conduct business with the public sector for a period not exceeding 10 years, in addition to any other remedies the National Treasury may have against the bidder/contractor concerned.

#### **13. SUPPLIER DUE DILIGENCE**

The National Department of Health reserves the right to conduct supplier due diligence prior to final award or at any time during the contract period. This may include site visits to assess whether an item is manufactured at the site specified in the bid and the site complies with quality criteria.

## 14. COMMUNICATION

The National Department of Health, may communicate with bidders where clarity is sought after the closing date and time of the bid and prior to the award of the contract, or to extend the validity period of the bid, if necessary.



Any communication to any government official or a person acting in an advisory capacity for the National Department of Health in respect of this bid between the closing date and the award of the bid by the bidder is discouraged.

All communication between the bidder and the National Department of Health, must be done in writing.

## **15. CONTACT DETAILS**

Directorate: Affordable Medicines Private Bag X828 **PRETORIA** 0001 Physical address Directorate: Affordable Medicines Civitas Building 242 Struben Street Cnr Thabo Sehume Street Pretoria 0002

Please use the following e-mail address for any queries relating to bidding process:

• tenders@health.gov.za

## **SECTION B**

## 16. CONTRACT PERIOD

The contract shall be for the period from 01 October 2021 to 30 September 2023.

## 17. PARTICIPATING AUTHORITES AND OTHER HEALTH ESTABLISHMENTS

Participating Authorities and Health Establishments which will be participating authorities in this contract are National Departments, Provincial Departments and orther institutions as approved by the accounting officer.

#### Provincial Departments:

- Eastern Cape;
- Free State;
- Gauteng;
- KwaZulu-Natal;
- Limpopo.

- Mpumalanga;
- Northern Cape;
- North West;
- Western Cape; and

#### Other Institutions:

• Nelson Mandela Childrens' Hospital

## 18. REGISTRATION ON DATABASES OF PARTICIPATING AUTHORITIES

All contracted suppliers must register on the supplier databases of Participating Authorities within 30 days after award of contract.

Failure to meet this requirement will result in the inability to process payment for goods.



## 19. POST AWARD PARTICIPATION

Regulation 16A6.6 of the Treasury Regulations for Departments, Trading Entities, Constitutional Entities and Public Entities, issued in terms of the Public Finance Management Act, 1999, (Act 1 of 1999), states that the Accounting Officer/Accounting Authority may, on behalf of a department, constitutional institution or public entity, request to participate in any contract arranged by means of a competitive bidding process by any organ of state, subject to the written approval of such organ of state and the relevant contractors.

## 20. AWARD CONDITIONS

The National Department of Health reserves the right to award contracts to more than one contractor for the same item.

The National Department of Health reserves the right to negotiate prices.

The National Department of Health reserves the right to award the same item as a multiple award to various contractors (two or more) to address high volume requirements, security of supply and product availability.

The following are examples of considerations which may be taken into account when contemplating a multiple award:

- Source of Active Pharmaceutical Ingredient (API) and actual manufacturing site;
- Capacity to meet expected demand as per published estimates in the Excel Bid Response Document;
- Estimated volume to be supplied;
- Risk to public health if the item is not available;
- Past compliance of the bidder with contractual obligations.

In cases where the tender does not achieve the most economically advantageous price, the National Department of Health reserves the right not to award that item. In the case of medicines for chronic conditions, pack sizes suitable for a 28-day treatment cycle are required. Should a 30-day or other pack size be offered, no conversion factor will be applied. Direct comparisons will be made between the 28-day and other pack sizes during evaluation. Similarly, no conversion factors will be applied in cases where a pack size other than that specified is offered.



The National Department of Health may change treatment protocols and/or product formulations where required, due to emerging clinical evidence, disease profiles, safety or resistance patterns and availability of items registered in terms of the Medicines and Related Substances Act, 1965, (Act 101 of 1965) at the date and time of bid closure. In these circumstances, the National Department of Health reserves the right to cancel the contract for an item, or adjust the quantity awarded based on expected changes in projected demand. The Department of Health will notify the contracted supplier within a reasonable time of the expected change. However, in cases where patient safety is a concern, these changes may be implemented with immediate effect.

## 20.1 SPLIT AND MULTIPLE AWARDS

The National Department of Health reserves the right to issue split or multiple awards, where necessary, to ensure security of supply.

The following will be taken into consideration when contemplating a split award:

- Source of API and manufacturing site.
- Capacity to meet expected demand as per published estimates in the Bid Response Document.
- Estimated volume to be supplied.
- Risk to public health if the item is not available.
- Past compliance of the bidder with contractual obligations.

Two-way split awards will be made in accordance with the following schedule based on the points scored:

Category	Difference between points scored	Recommended percentage split
A	Equal points	50/50
В	< 5 points	60/40
C	>5-10 points	70/30
D	>10-20 points	80/20
E	>20 points	90/10



Where a split for more than 2 suppliers is contemplated, the following formula may be used to allocate volumes for award:

- For a three way split: Supplier share = 33.3% + (supplier score mean score) x 2.3%
- For a four way split: Supplier share = 25% + (supplier score mean score) x 2%

## 20.2 THERAPEUTIC CLASS AWARDS

The Policy for Classifying Medicines into Therapetic Classes for Purposes of Therapeutic Interchange defines a therapeutic class as a group of medicines which have active ingredients with comparable therapeutic effects. Medicines in a therapeutic class may or may not belong to the same pharmacological class, may differ in chemistry or pharmacokinetic properties, and may possess different mechanisms of action, result in different adverse reactions, have different toxicity and drug interaction profiles. In most cases, these medicines have close similarity in efficacy and safety profiles, when administered in equipotent doses for a specific indication.

The ministerially appointed National Essential Medicines List Committee (NEMLC) formulates and revises the Standard Treatment Guidelines (STGs) and Essential Medicines List (EML). Therapeutic classes are mentioned in the "Medicine treatment" section of the national STGs which provides a class of medicines followed by an example such as, HMGCoA reductase ihibitors (Statins) e.g. simavastatin. These therapeutic classes have been designated where none of the members of the class offer any significant benefit over member of the class for a specific indication. The NEMLC will designate therapeutic classes for a condition, where appropriate.

Such therapeutic classes may be used during the contracting process to achieve the most economically advantageous contract, offer the market the largest volume and increase the number of competitors, thereby offering the opportunity for cost efficiencies by stimulating robust competition.

A single member of the class may be awarded.



Therapeutic	Therapeutic class description	Members of the therapeutic class
Class and Series		
Number		
Class 1	Echinocandins	Anidulafungin 100 mg injection, 1 vial
		VS
		Micafungin 100 mg injection, 1 vial
		VS
		Caspofungin 50 mg injection, 1 vial +
		Caspofungin 70 mg injection, 1 vial
Class 2	Antivirals for herpes zoster, herpes	Aciclovir 400mg tablets, 60 or 70 tablets
	simplex, varicella zoster	VS
		Valaciclovir 1000mg tablet, 30 tablets
		VS
		Famciclovir 250mg tablet, 21 tablets
Class 3	Fluoroquinolone eye drops	Ciprofloxacin 3mg/ml eye drops, 5ml
		vs
		Ofloxacin 3mg/ml eye drops, 5ml
		vs
		Moxifloxacin 5mg/ml eye drops, 5ml
Class 4	Imidazole, topical	Clotrimazole 1% cream, 20g
		vs
		Bifonazole 1% cream, 20g
		vs
		Miconazole 2% cream, 20 g
		vs
		Econazole 1% cream, 20g
		vs
		Ketoconazole 2% cream, 20g
Class 5	Praziquantel Procurement Class	Praziquantel 600mg tablet, 10 tablets
		vs
		Praziquantel 500mg tablet, 100 tablets



Class 6	Low Dose Macrolide Class	Azithromycin 200mg/5ml suspension, 15ml
		Vs
		Clarithromycin 125mg/5ml suspension, 50/60ml
Class 7	High Dose Macrolide Class	Clarithromycin 250mg/5ml suspension, 50/60ml
		vs
		Azithromycin 200mg/5ml suspension, 30ml
Class 8	Co-trimoxazole	Sulfamethoxazole and Trimethoprim 400/80mg
		tablet, 56 tablets
		vs
		Sulfamethoxazole and Trimethoprim 800/160mg
		tablet, 30 tablets

### 21 NEGOTIATIONS

The National Department of Health reserves the right to negotiate with the bidders prior to award and with the successful bidder(s) post award.

#### 22. NON-COMMITMENT

The National Department of Health reserves the right not to award, to award in part, or in full. The right is also reserved to withdraw or amend any of the bid conditions, by notice, in writing to all bidders prior to closing of the bid and post award

In the event that an incorrect award has been made, the National Department of Health reserves the right to remedy the matter in any manner it may deem fit.

### 23. PRICE REVIEW

The National Department of Health envisages three types of price review processes for the duration of this contract:

- A routine adjustment to mitigate foreign exchange fluctuations;
- An exceptional adjustment to mitigate significant short-term foreign exchange fluctuations; and
- A systematic review of prices for comparable products available in the international market place.



## 23.1 ELIGIBILITY RELATING TO RATE OF EXCHANGE ADJUSTMENTS

Eligibility for price adjustments relating to foreign exchange risk depends on: The submission of a complete price breakdown per instructions below for all relevant products; and

Assessment of the rationality of this price breakdown by the National Department of Health.

#### 23.1.1 INSTRUCTIONS FOR PRICE BREAKDOWN

- The price breakdown must be completed on the signed bid response document as well as the electronic version. The delivered price must be divided across five components
  - Active Pharmaceutical Ingredients (API);
  - Formulation;
  - Packaging;
  - Logistics (this includes transportation, warehousing and distribution);
  - Gross margin (remaining portion).
- The sum of these categories must be equal to 100% of the delivered price for the line item.
- The local + imported portions of the first three components must add up to 100% within each component (e.g. Portion of API attributable to local + Portion of API attributable to import = 100% of specific API component).
- VAT must be apportioned equally across all components and not regarded as a separate component.
- Labour must be apportioned appropriately across the relevant components.
- Breakdown must be in percentage format to the closest whole percentage (e.g. 20%).
- The National Department of Health reserves the right to engage with bidders to verify any of the components of the bid price, which may include audit of invoices and related documentation.

#### 23.2 PRICE ADJUSTMENTS RELATING TO FOREIGN EXCHANGE RISK

Only the portion of the bid price facing foreign exchange risk will be adjusted. This portion is determined by the price breakdown on the signed bid submission.

Adjustments are always calculated using the original awarded contracted price as the base.



Price adjustments relating to foreign exchange will be based on the percentage change between the relevant base average rate of exchange (RoE) and an adjustment average RoE. Rates are sourced from the Reserve Bank (www.resbank.co.za).

Eligibility for favourable Contractual Price Adjustments may be withdrawn in light of evidence of poor compliance with contractual obligations.

Currency	Base Average Rates of Exchange Average for the period 1 April 2020 to 30 September 2020
Rand per US Dollar	17.03
Rand per Br Pound	21.33
Rand per Euro	19.74
Rand per Yuan Renminbi	2.48
Rand per Indian Rupee	0.23
Rand per Danish Krone	2.65

#### Base average RoE for this tender will be as follows, per currency:

Should the bidder make use of any currency not mentioned above, the bidder must stipulate this clearly and submit the calculated average RoE for the period 1 January 2020 to 30 June 2020using the South African Reserve Bank published rates for the specific currency.

#### 23.3 APPLICATION FOR CONTRACTUAL PRICE ADJUSTMENTS

Scanned copies of signed applications for price adjustments must be received by the National Department of Health prior to the submission dates detailed in the tables below.

Where no application for an adjustment relating to foreign exchange has been received and such an adjustment would be favourable to the Department, this will be implemented automatically.

Foreign exchange adjustments may never result in a price exceeding the current Single Exit Price, ex Logistics.



### 23.4 ROUTINE PRICE ADJUSTMENTS

Schedules for routine price reviews, and periods for calculating adjustment average RoE are detailed in the table below:

Review	Period for calculating adjustment average RoE	Submission of request for proce review to reach the office by	Date from which adjusted prices will become effective
1	01 October 2021 - 31 March 2022	02 April 2022	01 May 2022
2	01 April 2022 - 30 September 2022	03 October 2022	01 November 2022
3	01 October 2022 - 31 March 2023	03 April 2023	01 May 2023

### 23.5 EXCEPTIONAL PRICE ADJUSTMENTS

Suppliers may request exceptional price adjustments according to the schedule in the table below. These will be activated if the absolute change between the base RoE and the three month retrospective average RoE indicated in the table below fluctuates by more than 10%.

Review	Period for calculating adjustment average RoE	Submission of request for proce review to reach the office by	Date from which adjusted prices will become effective
0.1	01 October 2021 - 31 December 2021	03 January 2022	01 February 2022
1.1	01 April 2022 - 31 June 2022	02 July 2022	01 August 2022
2.1	01 October 2022 - 31 December 2022	03 January 2023	01 February 2023
3.1	01 April 2023 - 31 June 2023	03 July 2023	01 July 2023

Suppliers who received exceptional adjustments will receive routine adjustments based on the preceding three months, rather than the usual six month historical average exchange rate. The periods for calculating adjustment average RoE in these instances are detailed in the table below:



Review	Period for calculating adjustment average RoE	Submission of request for proce review to reach the office by	Date from which adjusted prices will become effective
1	01 January 2022 - 31 March 2022	02 April 2022	01 May 2022
2	01 July 2022 - 30 September 2022	03 October 2022	01 November 2022
3	01 January 2023 - 31 March 2023	03 April 2023	01 May 2023

### 23.6 PRICE ADJUSTMENTS BASED ON A SYSTEMATIC REVIEW

The National Department of Health reserves the right to review international prices to identify lowest comparable global prices.

Where this review identifies any prices that are lower than contract prices the National Department of Health will enter into price negotiations with the contracted supplier.

Where the outcome of this negotiation is deemed unfavourable, the National Department of Health reserves the right to terminate the award for the item in question.

## 24. QUALITY

Products must conform to the conditions of registration of the product in terms of the Medicines and Related Substances Act, 1965 (Act 101 of 1965) for the full duration of this contract.



## 25. DELIVERY AND QUANTITIES

### **25.1 DELIVERY BASIS**

Firm lead times for delivery must be quoted for the duration of the contract period.

Transit and storage conditions applicable to the relevant products must be adhered to.

The initial lead time as proposed in the bid response document will be calculated from date of award of the contract and NOT the date of placement of the first order. This period may not exceed 75 calendar days from the date of award.

Lead time within the contract period is defined as the time from submission of order to supplier to time of receipt by the Department, as confirmed by the Proof of Delivery document. This lead time may not exceed 14 calendar days.

Failure to comply with the contractual lead time will result in penalties being enforced as per paragraph 21 and 22 of the General Conditions of Contract.

#### **25.2 QUANTITIES**

The quantities reflected in the bid are estimated quantities and no guarantee is given or implied as to the actual quantity which will be procured during the contract period.Fluctuations in monthly demand may occur. Proposed minimum order quantities (MOQs) should facilitate delivery directly to health establishments. The National Department of Health reserves the right to negotiate MOQs where necessary. Where consensus regarding MOQs cannot be reached, the bid may not be awarded.

Suppliers are required to maintain sufficient buffer stock to meet at least two-months demand for all items, aligned with the needs of Participating Authorities.



# **SECTION C**

## 26. SUPPLIER PERFORMANCE MANAGEMENT

**26.1 Supplier performance management** will be the responsibility of Participating Authorities with oversight from the National Department of Health and, where supplier performance disputes cannot be resolved between the contractor and the Participating Authority, National Treasury: Transversal Contracting Chief Directorate and National Department of Health must be informed for corrective action.

The National Department of Health, in collaboration with the Participating Authorities, will monitor the performance of contracted suppliers in terms of this contract, including but not limited to the following:

- Compliance with reporting requirements according to reporting schedule and reporting mechanism.
- As a minimum, suppliers will be required to submit the following information in a specified format and via a mechanism defined by the National Department of Health:
  - All transactional data relating to orders;
  - A monthly age analysis;
  - Production pipeline data and forecast including:
  - Number of units of the item available (stock on hand);
  - Number of units of the item in Quality Assurance, awaiting release;
  - Number of units of the item in the current month's production plan.
  - Status of outstanding orders.
- Attendance of compulsory quarterly meetings
  - The National Department of Health will hold quarterly meetings with suppliers which will include, but not be limited to, a review of supplier performance and forecasted demand for the next quarter. Suppliers may be required to present continuous improvement initiatives aimed at improving efficiencies in the supply chain to benefit both suppliers and the Department of Health.
- The Participating Authorities shall impose penalties, where deemed necessary, as per Paragraph 21 and 22 of the General Conditions of Contract.
- Non-compliance of contracted suppliers to the terms and conditions of this contract may influence participation in future contracts.



- Contractors should note that each individual purchasing institution is responsible for generating the order(s) as well as for the payment(s) thereof.
- Contractors should note that the order(s) will be placed as and when required during the contract period and delivery points will be specified by the relevant purchasing institution(s).
- The instructions appearing on the official order form regarding the supply, dispatch and submission of invoices must be strictly adhered to and under no circumstances should the contractor deviate from the orders issued by the purchasing institutions.
- The Department of Health is under no obligation to accept any quantity which is in excess of the ordered quantity.
- In order to facilitate efficient implementation of the direct delivery strategy, contracted suppliers must pack orders for the health establishment as per the purchase order.
- Only orders made using an official, authorised purchase order format are valid.
- Suppliers are required to acknowledge receipt of all purchase orders received from Participating Authorities, in a manner stipulated by the relevant Participating Authority.
- Changes to any quantities ordered may only be made upon receipt of an amended purchase order.
- The Participating Authorities reserve the right to cancel orders where the lead time exceeds the delivery lead time specified in the contract and may, at their discretion, purchase supplies of a similar quality and up to the same quantity in substitution of the goods not supplied in conformity with the contract (as per paragraph 21.6 of the General Conditions of Contract).
- In cases where an order is received which appears to be irrational or misaligned with estimates, the contracted supplier must liaise with the relevant Participating Authority prior to processing the order.

### 26.2 DELIVERY ADHERENCE

- Products and related documentation must be delivered in accordance with the terms, conditions and delivery instructions stipulated on the purchase order.
- The information on invoices and documents relating to delivery must comply with the minimum data requirements as defined by the National Department of Health.
- Invoices must reflect both the "proprietary name "(brand name"/"trade name") which is unique to a particular medicine, and which is the name approved in terms of section 15(4) of the Medicines and Related Substances Act, 1965 (Act 101 of 1965), and the item description as it appears in the contract circular and Master Procurement Catalogue (MPC), or Master Health Product List (MHPL), which will replace the MPC.



- Original invoices and proof of delivery must be authorised by a delegated official at the designated delivery
  point. These documents must be delivered to the authority responsible for payment. This may or may not
  be the same as the delivery address stipulated on the purchase order. Suppliers are required to know where
  documents must be delivered.
- The supplier must ensure that products are delivered in accordance with the appropriate conditions of storage, as per product's conditions of registration. Delivery is deemed to terminate upon signature of receipt by the delegated official.
- Discrepancies between invoice and physical stock, or damaged stock, will be reported to the contracted supplier within a reasonable time or as arranged with the supplier. This time period must make provision for the quantities received to be checked upon receipt of delivery.
- Contracted suppliers will be responsible for collection of goods delivered erroneously, or in the incorrect condition as formally arranged in consultation with the purchasing authority. The Participating Authorities may recoup any expenses associated with failure to collect such goods in accordance with the agreement

#### 26.3 CONTINUITY OF SUPPLY

- Contracted suppliers must have at least two months' supply of the estimate at the start of the contract.
- Contractors must maintain sufficient buffer stock throughout the duration of the contract.
- Contractors must inform National Department of Health at first knowledge of any circumstances that may result in interrupted supply, including but not limited to:
  - regulatory action which may impact on their GMP status or that of entities on which they are reliant;
  - any anticipated problems associated with the availability of active pharmaceutical ingredient (API);
  - industrial action
  - challenges with manufacturing pipeline;
  - any other supply challenges.
- Contractors must direct official communication relating to continuity of supply to stockalert@health.gov.za, as well as Participating Authorities.
- Contractors must direct official communication relating to payment challenges to medacc@health.gov.za, as well as Participating Authorities.
- All official communication must include detail of corrective actions taken by the contracted supplier to ensure continuity of supply.



- It is the responsibility of the contracted supplier to ensure continuous availability and supply of contracted items. In the event that the contracted supplier is unable to supply, the contracted supplier id required to source alternative product of acceptable quality and up to the same quantity as required for a period of not more than three months. In the case of a multiple award, the alternative product should not be sourced from another contracted supplier for the same product.
- In the event that a contracted supplier is unable to supply in the short term, the National Department of Health reserves the right to proportionally reallocate volumes to an alternative contracted supplier for the duration of the contracted supplier's inability to supply.
- Prior to the supply of an alternative product can be undertaken, the contracted supplier is required to submit the samples of the product to be supplied to the two health establishments as listed in section 4. The contracted supplier is also required to furnish the Department of Health with the following information:
- Name of the product to be supplied;
- The quantities to be supplied;and
- The period for which the product will be supplied.
- The alternative productmust be supplied at the current price of the contracted item.
- This provision is only applicable for emergency supply and cannot be used for routine and continuous supply of the product.
- Suppliers may be required to pay penalties for supply exceeding the contractual lead time as stipulated in the General Conditions of Contract Paragraph 22.
- In terms of the General Conditions of Contract and Special Requirements and Conditions of Contract, the Participating Authorities may purchase outside the contract in order to meet its requirements if the item is urgently required and is not immediately available.

#### 26.4 REPORTING

National Department of Health will provide the requirements for reporting and successful bidders will be assisted with complying with these requirements.

The National Department of Health may, from time to time and within reason, add to the reporting requirements. Any changes to reporting requirements or the reporting mechanism will be communicated in writing by the Directorate: Affordable Medicines.

### 27. PACKAGING, LABELLING AND BARCODES



### 27.1 PACKAGING

- Suppliers must ensure that products delivered are received in good order at the point of delivery. Packaging must be suitable for further dispatch, storage and stacking according to Good Wholesaling Practice and Good Distribution Practice.
- Packaging must be suitable for transportation and should prevent exposure to conditions that could adversely affect the stability and integrity of the product.
- The packaging must be uniform for the duration of the contract period. All products must be packaged in acceptable containers, specifically developed for the product.
- The number of units per shipper pack or original carton must be completed in the Bid Response Document.
- Where a particular stacking and storage configuration is recommended by the supplier, this should be clearly illustrated on the outer packaging.
- Where the contents of the shipper pack represent a standard supply quantity of an item, the following must be adhered to:
  - Outer packaging flanges must be sealed with suitable tape that will clearly display evidence of tampering;.
  - The contents must be packed in neat, uniform rows and columns that will facilitate easy counting when opened.
  - Where the contents of a shipper pack represent a non-standard supply quantity, the following must be adhered to:
  - Outer packaging flanges must be sealed with suitable tape that will clearly display evidence of tampering;.
  - The shipper pack must contain only one product, mixing of multiple products in a single shipper is not allowed;.
  - The outer packaging must be clearly marked as a "Part Box".



### 27.2 LABELLING

- All containers, packaging and cartons must be clearly labelled. Bulk packs must be labelled in letters not less than font size 48.
- The following information must be clearly and indelibly printed on all shipper packs, including any part boxes:
  - Item name as contained in the contract circular and the Master Procurement Catalogue (MPC), or Master Health Products List (MHPL), which will replace the MPC.
  - Registered product name (if applicable);
  - Number of units in pack
  - Batch number;
  - Expiry date;
  - Storage conditions;
  - Barcode.
- Where the contents of the shipper pack require special attention in terms of storage and/or handling,
   e.g. thermolabile, high-scheduled or cytotoxic products, such instructions must be clearly and visibly indicated on the outer packaging on a brightly coloured background.
- Unit packs must be labelled in accordance with Regulation 10 of the General Regulations published in terms of the Medicines and Related Substances Act, 1965 (Act 101 of 1965). The label must include a barcode suitable for the identification and tracking of medication.

### 27.3 BARCODES

- All unit and shipper packs must be marked with the appropriate barcode number and symbology.
- The European Article Numbering Code 13 (EAN 13) has been accepted as standard.
- Suppliers are encouraged to include a 2D barcode or similar on their packaging that will include the following information:
  - Item name as contained in the contract circular and the Master Procurement Catalogue (MPC), or Master Health Products List (MHPL) which will replace the MPC.
  - The "proprietary name (brand name"/"trade name") unique to a particular medicine, as approved by MCC or SAHPRA;
    - Dosage form and strength;
    - Pack size;



- Batch number;
- Expiry date.

## 28 SHELF LIFE

- Unless MCC or SAHPRA, has approved a shorter shelf life, products must have a shelf-life of at least 12 months upon delivery.
- Contracted suppliers may apply in writing to Participating Authorities to supply a product with a shorter shelf life provided that:
  - Applications are accompanied by an undertaking that such short-dated products will be unconditionally replaced or credited before or after expiry; and
  - Applications are approved by the Participating Authorities before execution of orders; and
  - Upon notification of remaining expired stock such products will be collected by the supplier at their own cost; and
  - Failure to collect the products within 30 days after written notification to the supplier will result in the disposal of the product by the Participating Authority for the account of the supplier.
- If short-dated products are delivered without the aforementioned undertaking the following discount formula will be applied for invoicing of short-dated products:
  - A = (12 months to date of expiry) x 2% x consignment value short dated product. Therefore, amount to be invoiced is: Consignment value minus A, where A is the value of the outcome of the discount formula.
- Unless otherwise agreed to, any Participating Authority may, without prejudice, decline to accept product with a shelf-life of less than 12 months.

### 29. CEDING, MERGERS, TAKE OVERS AND CHANGES IN SUPPLIER DETAILS

Where a contracted supplier plans to merge with, or is going to be acquired by, another entity or plans to cede a contract the contracted supplier must inform the National Department of Health in writing at first knowledge of such an event.

Where a contracted supplier plans to cede a contrated item to another supplier, the contracted supplier must submit an official request in writing to the NDOH, three months prior to the proposed effective date.



The NDOH reserves the right to accept or decline the request to cede the contractual obligations to the new supplier under the prevailing conditions of contract or to cancel the contract.

The contracted supplier is obliged to supply the contracted item under the prevailaing conditions of contract, until such time that the NDOH has approved the request to cede the item to another supplier.

The contracted supplier must inform the National Department of Health at first knowledge of any changes to address, name, or contact details and effect these changes on the Central Supplier Database.

### **30. CANCELLATION OF THE CONTRACT**

Cancellation of a contract will only be considered after compelling evidence to support the request has been submitted to the satisfaction of the Department of Health.

The contracted supplier is obliged to supply the contracted item under the prevailaing conditions of contract, until such time that the NDOH has approved the request to cancel the item.

### **31. THIRD PARTIES**

Participating Authorities will not make a payment to or consult with a third party. No third party is entitled to put an account of a Participating Authority on hold.

END

Item No	Description	Therapeutic Class Numbers	Unit	Estimate
1	Aciclovir 200mg tablet, 25 tablets		Pack of 25 tablets	349 540
2	Aciclovir 250mg injection, 1 vial		Each	223 600
3	Aciclovir 400mg tablets, 60 or 70 tablets	Class 2	Pack of 60 or 70 tablets	313 890
4	Aciclovir solution 200mg/5ml, 125ml		Each	17 980
5	Albendazole 100mg/5ml suspension, 20ml		Each	1 542 830
6	Albendazole 400mg tablet, 1 tablet		Pack of 1 tablet	1 695 910
7	Amikacin 100 mg injection, 2ml		Each	155 000
8	Amikacin 250 mg injection, 2ml		Each	31 810
9	Amikacin 500 mg injection, 2ml		Each	308 590
10	Amoxicillin 125mg/5ml suspension, 100ml		Each	4 577 710
11	Amoxicillin 250mg capsule, 100 capsules		Pack of 100 capsules	30 700
12	Amoxicillin 250mg capsule, 15 capsules		Pack of 15 capsules	6 708 320
13	Amoxicillin 250mg/5ml suspension, 100ml		Each	5 967 140
14	Amoxicillin 500mg capsule, 15 capsules		Pack of 15 capsules	13 815 720
15	Amoxicillin 500mg capsules, 100 capsules		Pack of 100 capsules	84 960
16	Amoxicillin and Clavulanic acid 1000/200mg, injection, 1 vial		Each	9 173 040
17	Amoxicillin and Clavulanic acid 125mg and 31.25mg/5ml suspension, 100ml		Each	1 265 080
18	Amoxicillin and Clavulanic acid 250/125mg capsule/tablet, 15 capsules/tablets		Pack of 15 capsules/tablets	2 876 650
19	Amoxicillin and Clavulanic acid 250mg and 62.5mg/5ml suspension, 100ml		Each	683 410
20	Amoxicillin and Clavulanic acid 500/100mg, injection, 1 vial		Each	1 745 620
21	Amoxicillin and Clavulanic Acid 600mg and 42.9mg/5ml suspension, 100ml		Each	171 500
22	Amoxicillin and Clavulanic acid 875/125mg capsule/tablet, 10 capsules/tablets		Pack of 10 capsules/tablets	2 905 350
23	Amphotericin B 50mg injection, 1 vial		Each	212 210
24	Ampicillin 250mg injection, 1 vial		Each	1 821 760

Item No	Description	Therapeutic Class Numbers	Unit	Estimate
25	Ampicillin 500mg injection, 1 vial		Each	6 526 840
26	Anidulafungin 100 mg injection, 1 vial	Class 1	Each	11 750
27	Artemether and Lumefantrine 20/120mg tablet, 24 tablets		Pack of 24 tablets	64 060
28	Artesunate 60mg injection, 1 vial		Each	453 675
29	Azithromycin 200mg/5ml suspension, 15ml	Class 6	Each	642 470
30	Azithromycin 200mg/5ml suspension, 30ml	Class 7	Each	3 412
31	Azithromycin 250mg tablet/capsule, 3 tablets/capsules		Pack of 3 tablets/capsules	1 120 440
32	Azithromycin 500mg injection, 1 vial		Each	58 500
33	Azithromycin 500mg tablet/capsule, 2 tablets/capsules		Pack of 2 tablets/capsules	2 417 170
34	Azithromycin 500mg tablet/capsule, 3 tablets/capsules		Pack of 3 tablets/capsules	6 325 530
35	Benzathine Benzylpenicillin 1.2 million unit injection, 1 vial		Each	386 240
36	Benzathine Benzylpenicillin 2.4 million unit injection, 1 vial		Each	412 110
37	Benzylpenicillin 1 million unit injection, 1 vial		Each	298 720
38	Benzylpenicillin 5 million unit injection, 1 vial		Each	141 280
39	Bifonazole 1% cream, 20g	Class 4	Each	3 656 850
40	Caspofungin 50 mg injection, 1 vial [Items 40 and 41 will be considered as a series]	Class 1 Series 1	Each	11 750
41	Caspofungin 70 mg injection, 1 vial [Items 40 and 41 will be considered as a series]	Class 1 Series 1	Each	1 176
42	Cefalexin 125mg/5ml suspension, 100ml		Each	802 700
43	Cefalexin 250mg capsule/tablet, 20 capsules/tablets		Pack of 20 capsules/tablets	117 400
44	Cefalexin 250mg/5ml suspension, 100ml		Each	25 450
45	Cefalexin 500mg capsule/tablet, 20 capsules/tablets		Pack of 20 capsules/tablets	31 270
46	Cefazolin 1g injection, 1 vial		Each	4 256 430
47	Cefazolin 500mg injection, 1 vial		Each	1 363 190
48	Cefepime 1g injection, 1 vial		Each	34 080

Item No	Description	Therapeutic Class Numbers	Unit	Estimate
49	Cefepime 2g injection, 1 vial		Each	59 350
50	Cefotaxime 1g injection, 1 vial		Each	295 450
51	Cefotaxime 500mg injection, 1 vial		Each	188 080
52	Ceftazidime 1g injection, 1 vial		Each	64 600
53	Ceftazidime 2g injection, 1 vial		Each	19 395
54	Ceftriaxone 1g injection, 1 vial		Each	9 622 350
55	Ceftriaxone 250mg injection, 1 vial		Each	5 288 630
56	Ceftriaxone 500mg injection, 1 vial		Each	3 217 940
57	Chloramphenicol 0,5% eye drops, 0,5ml single use disposable applicator, 20 applicators		Pack of 20 applicators	10 070
58	Chloramphenicol 0,5% eye drops,10ml		Each	18 770
59	Chloramphenicol 1% eye ointment, 3.5g		Each	6 057 610
60	Ciprofloxacin 250mg tablet, 10 tablets		Pack of 10 tablets	463 090
61	Ciprofloxacin 2mg/ml injection, 100ml		Each	144 430
62	Ciprofloxacin 2mg/ml injection, 200ml		Each	86 320
63	Ciprofloxacin 3mg/ml eye drops, 5ml	Class 3	Each	255 400
64	Ciprofloxacin 500mg tablet, 10 tablets		Pack of 10 tablets	2 055 560
65	Ciprofloxacin oral suspension 250mg/5ml 100ml		Each	125 424
66	Clarithromycin 125mg/5ml suspension, 50/60ml	Class 6	Each	642 470
67	Clarithromycin 250mg/5ml suspension, 50/60ml	Class 7	Each	3 412
68	Clarithromycin 500mg tablet, 14 tablets		Pack of 14 tablets	29 800
69	Clindamycin 150mg capsule, 100 capsules		Pack of 100 capsules	4 220
70	Clindamycin 150mg capsule, 20 capsules		Pack of 20 capsules	74 740
71	Clindamycin 600mg injection, 1 vial		Each	208 500
72	Clotrimazole 1% cream, 20g	Class 4	Each	3 656 850

#### ITEM LIST

Item No	Description	Therapeutic Class Numbers	Unit	Estimate
73	Clotrimazole 500mg vaginal tablet, Unit pack: 1 tablet and applicator		Pack of 1 tablet and applicator	923 510
74	Clotrimazole 500mg/50g vaginal cream, Unit pack: 50g tube + 6 applicators		Pack of 50g tube and 6 applicators	599 270
75	Cloxacillin 250mg injection, 1 vial		Each	249 900
76	Cloxacillin 500mg injection, 1 vial		Each	1 070 630
77	Dapsone 100mg tablet, 100 tablets		Pack of 100 tablets	22 290
78	Dexamethasone and Chloramphenicol 0.1% / 0.5% eye drops, 5ml		Each	171 340
79	Doxycycline 100mg capsule/tablet, 100 capsules/tablets		Pack of 100 capsules/tablets	17 580
80	Doxycycline 100mg capsule/tablet, 14 capsules/tablets		Pack of 14 capsules/tablets	1 955 460
81	Econazole 1% cream, 20g	Class 4	Each	3 656 850
82	Ertapenem 1g injection, 1 vial		Each	154 520
83	Famciclovir 250mg tablet, 21 tablets	Class 2	Pack of 21 tablets	313 890
84	Flucloxacillin 250mg capsule, 100 capsules		Pack of 100 capsules	100 860
85	Flucloxacillin 250mg capsule, 20 capsules		Pack of 20 capsules	3 745 160
86	Flucloxacillin 250mg capsule, 40 capsules		Pack of 40 capsules	3 093 670
87	Fluconazole 200mg tablet/capsule, 28 tablets/capsules		Pack of 28 tablets/capsules	490 310
88	Fluconazole 2mg/ml injection, 100ml injection		Each	281 145
89	Fluconazole 50mg tablet/capsule, 14 tablets/capsules		Pack of 14 tablets/capsules	203 640
90	Fluconazole 50mg/5ml syrup, 35ml		Each	91 990
91	Fosfomycin 3g sachet, 1 sachet		Each	990 450
92	Ganciclovir 500mg injection, 1 vial		Each	38 395
93	Gentamicin 20mg injection, 2ml injection		Each	633 215
94	Gentamicin 80mg injection, 2ml injection		Each	1 741 860
95	Imipenem and cilastatin, 500/500mg injection, 1 vial		Each	275 460
96	Ketoconazole 2% cream, 20g	Class 4	Each	3 656 850

Item No	Description	Therapeutic Class Numbers	Unit	Estimate
97	Ketoconazole 200mg tablet, 30 tablets		Pack of 30 tablets	7 610
98	Linezolid 100mg/5ml suspension, 150ml		Each	2 480
99	Linezolid 600mg injection, 300ml infusion		Each	34 270
100	Linezolid 600mg tablet, 10 tablets		Pack of 10 tablets	278 980
101	Mebendazole 100mg tablet, 6 tablets		Pack of 6 tablets	3 112 300
102	Mebendazole 100mg/5ml, suspension, 30ml		Each	681 400
103	Mebendazole 500mg tablet, 1 tablet		Pack of 1 tablet	9 801 190
104	Meropenem 1g injection, 1 vial		Each	507 710
105	Meropenem 500mg injection, 1 vial		Each	325 140
106	Metronidazole 200mg tablet, 21 tablets		Pack of 21 tablets	1 624 750
107	Metronidazole 200mg tablet, 250 tablets		Pack of 250 tablets	56 450
108	Metronidazole 200mg tablet, 28 tablets		Pack of 28 tablets	383 750
109	Metronidazole 200mg/5ml suspension, 100ml		Each	1 208 620
110	Metronidazole 400mg tablet, 100 tablets		Pack of 100 tablets	98 560
111	Metronidazole 400mg tablet, 14 tablets		Pack of 14 tablets	2 363 960
112	Metronidazole 400mg tablet, 21 tablets		Pack of 21 tablets	1 034 170
113	Metronidazole 400mg tablet, 5 tablets		Pack of 5 tablets	4 252 140
114	Metronidazole 500mg injection		Each	4 740 100
115	Micafungin 100 mg injection, 1 vial	Class 1	Each	11 750
116	Micafungin 50 mg injection, 1 vial		Each	10 365
117	Miconazole 2% cream, 20 g	Class 4	Each	3 656 850
118	Miconazole 2% oral gel, 30g		Each	338 720
119	Moxifloxacillin 400mg injection, 250ml vial		Each	3 692
120	Moxifloxacin 400mg tablet, 10 tablets		Pack of 10 tablets	2 540

Item No	Description	Therapeutic Class Numbers	Unit	Estimate
121	Moxifloxacin 400mg tablet, 5 tablets		Pack of 5 tablets	7 670
122	Moxifloxacin 5mg/ml eye drops, 5ml	Class 3	Each	255 400
123	Natamycin 50mg/ml eye drops, 15ml		Each	814
124	Neomycin and Polymyxin B sulfates and Dexamethasone, 3.5mg, 6000U and 1mg per ml eye drops, 5ml		Each	272 160
125	Neomycin and Polymyxin B sulfates and Dexamethasone, 3.5mg, 6000U and1mg per gram eye ointment, 3.5g		Each	131 390
126	Nitrofurantoin 100mg capsule, 50 capsules		Pack of 50 capsules	88 820
127	Nystatin 100 000 units/ml oral suspension, 20ml + calibrated dropper		Pack of 20ml and calibrated dropper	1 983 280
128	Ofloxacin 3mg/ml eye drops, 5ml	Class 3	Each	255 400
129	Phenoxymethylpenicillin 125mg/5ml suspension, 100ml		Each	827 720
130	Phenoxymethylpenicillin 250mg tablet, 100 tablets		Pack of 100 tablets	13 500
131	Phenoxymethylpenicillin 250mg tablet, 40 tablets		Pack of 40 tablets	2 057 220
132	Phenoxymethylpenicillin 250mg/5ml suspension, 100ml		Each	1 544 640
133	Piperacillin and Tazobactam 4g/500mg injection, 50ml injection		Each	1 289 630
134	Praziquantel 500mg tablet, 100 tablets	Class 5	Pack of 100 tablets	5 331
135	Praziquantel 600mg tablet, 10 tablets	Class 5	Pack of 10 tablets	53 250
136	Silver Sulfadiazine 1% cream, 250g		Each	36 140
137	Silver Sulfadiazine 1% cream, 500g		Each	103 260
138	Silver Sulfadiazine 1% cream, 50g		Each	228 740
139	Sulfamethoxazole and Trimethoprim 200/40mg per 5ml suspension, 100ml		Each	6 845 430
140	Sulfamethoxazole and Trimethoprim 400/80mg injection, 5ml injection		Each	625 150
141	Sulfamethoxazole and Trimethoprim 400/80mg tablet, 28 tablets		Pack of 28 tablets	3 001 560
142	Sulfamethoxazole and Trimethoprim 400/80mg tablet, 100 tablets		Pack of 100 tablets	293 430
143	Sulfamethoxazole and Trimethoprim 400/80mg tablet, 56 tablets	Class 8	Pack of 56 tablets	6 885 080
144	Sulfamethoxazole and Trimethoprim 800/160mg tablet, 30 tablets	Class 8	Pack of 30 tablets	6 885 080

Item No	Description	Therapeutic Class Numbers	Unit	Estimate
145	Tobramycin 3mg/g eye ointment, 3.5 g		Each	65 124
146	Tobramycin 3mg/ml eye drops, 5ml		Each	103 638
147	Valaciclovir 1000mg tablet, 30 tablets	Class 2	Pack of 30 tablets	313 890
148	Valganciclovir 450mg tablet, 60 tablets		Pack of 60 tablets	2 669
149	Valganciclovir 50mg/ml suspension, 100ml		Each	3 021
150	Vancomycin 1g injection, 1 vial		Each	181 590
151	Vancomycin 500mg injection, 1 vial		Each	241 830